Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test by Kyrgiou, Maria et al.
Cochrane Database of Systematic Reviews
Immediate referral to colposcopy versus cytological
surveillance for minor cervical cytological abnormalities in
the absence of HPV test (Review)
Kyrgiou M, Kalliala IEJ, Mitra A, Fotopoulou C, Ghaem-Maghami S, Martin-Hirsch PPL,
Cruickshank M, Arbyn M, Paraskevaidis E
Kyrgiou M, Kalliala IEJ, Mitra A, Fotopoulou C, Ghaem-Maghami S, Martin-Hirsch PPL, Cruickshank M, Arbyn M, Paraskevaidis E.
Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test.
Cochrane Database of Systematic Reviews 2017, Issue 1. Art. No.: CD009836.
DOI: 10.1002/14651858.CD009836.pub2.
www.cochranelibrary.com
Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
(Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
6BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
20DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
23REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
27CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
37DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Occurence of CIN2+ at different lengths of follow-up: immediate colposcopy versus cytological
surveillance, Outcome 1 Occurrence of CIN2+. . . . . . . . . . . . . . . . . . . . . . . 40
Analysis 2.1. Comparison 2 Occurence of CIN3+ at different lengths of follow-up: immediate colposcopy versus cytological
surveillance, Outcome 1 Occurrence of CIN3+. . . . . . . . . . . . . . . . . . . . . . . 41
Analysis 3.1. Comparison 3 Histology at 12 months: immediate colposcopy versus cytological surveillance, Outcome 1
Presence of any CIN in histology at 12 months. . . . . . . . . . . . . . . . . . . . . . . 42
Analysis 3.2. Comparison 3 Histology at 12 months: immediate colposcopy versus cytological surveillance, Outcome 2
Presence of CIN1/2 in histology at 12 months. . . . . . . . . . . . . . . . . . . . . . . 43
Analysis 3.3. Comparison 3 Histology at 12 months: immediate colposcopy versus cytological surveillance, Outcome 3
Presence of CIN3+ in histology at 12 months. . . . . . . . . . . . . . . . . . . . . . . 44
Analysis 4.1. Comparison 4 Histology at 24 months: immediate colposcopy versus cytological surveillance, Outcome 1
Histology at 24 months. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Analysis 5.1. Comparison 5 Occurence of CIN2 at different lengths of follow-up: Immediate colposcopy versus cytological
surveillance, Outcome 1 Occurrence of CIN2. . . . . . . . . . . . . . . . . . . . . . . 47
Analysis 6.1. Comparison 6 Default rates: immediate colposcopy versus cytological surveillance, Outcome 1 Default
rates. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Analysis 7.1. Comparison 7 Histology at 24 months: immediate colposcopy versus cytological surveillance, LSIL/mild
dyskaryosis only, Outcome 1 CIN incidence at 24 months, after LSIL/mild dyskaryosis at baseline. . . . . 49
Analysis 8.1. Comparison 8 Histology at 24 months: immediate colposcopy versus cytological surveillance, excluding 1
trial, Outcome 1 Presence of CIN2 in histology at 24 months. . . . . . . . . . . . . . . . . . 50
Analysis 8.2. Comparison 8 Histology at 24 months: immediate colposcopy versus cytological surveillance, excluding 1
trial, Outcome 2 Presence of CIN2+ in histology at 24 months. . . . . . . . . . . . . . . . . 51
Analysis 8.3. Comparison 8 Histology at 24 months: immediate colposcopy versus cytological surveillance, excluding 1
trial, Outcome 3 Presence of CIN3+ in histology at 24 months. . . . . . . . . . . . . . . . . 52
52ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
57APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
60WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
60HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
61CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
61DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
61SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iImmediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
(Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
62DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
iiImmediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
(Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Immediate referral to colposcopy versus cytological
surveillance for minor cervical cytological abnormalities in
the absence of HPV test
Maria Kyrgiou1,2a , Ilkka E J Kalliala1,2b, Anita Mitra2, Christina Fotopoulou1 ,2, Sadaf Ghaem-Maghami1,2, Pierre PLMartin-Hirsch
3, Margaret Cruickshank4, Marc Arbyn5c , Evangelos Paraskevaidis6d
1West London Gynaecological Cancer Centre, Queen Charlotte’s & Chelsea, Hammersmith Hospital, Imperial NHS Healthcare
Trust, London, UK. 2The Institute of Reproductive and Developmental Biology (IRDB), Surgery and Cancer, Imperial College
London, London, UK. 3Gynaecological Oncology Unit, Royal Preston Hospital, Lancashire Teaching Hospital NHS Trust, Preston,
UK. 4Obstetrics and Gynaecology, Aberdeen Royal Infirmary, Aberdeen, UK. 5Unit of Cancer Epidemiology, Belgian Cancer Centre,
Scientific Institute of Public Health, Brussels, Belgium. 6Department of Obstetrics and Gynaecology, Ioannina University Hospital,
Ioannina, Greece
aJoint first author. bJoint first author. cJoint senior author. d Joint senior author
Contact address: Maria Kyrgiou, West London Gynaecological Cancer Centre, Queen Charlotte’s & Chelsea, Hammersmith Hospital,
Imperial NHS Healthcare Trust, Du Cane Road, London, W12 0NN, UK. m.kyrgiou@imperial.ac.uk, mkyrgiou@yahoo.com.
Editorial group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group.
Publication status and date: Edited (no change to conclusions), published in Issue 2, 2017.
Review content assessed as up-to-date: 21 April 2016.
Citation: Kyrgiou M, Kalliala IEJ, Mitra A, Fotopoulou C, Ghaem-Maghami S, Martin-Hirsch PPL, Cruickshank M, Ar-
byn M, Paraskevaidis E. Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnor-
malities in the absence of HPV test. Cochrane Database of Systematic Reviews 2017, Issue 1. Art. No.: CD009836. DOI:
10.1002/14651858.CD009836.pub2.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
A significant number of women are diagnosed with minor cytological abnormalities on cervical screening. Many authorities recommend
surveillance as spontaneous regression might occur. However, attendance for cytological follow-up decreases with time and might put
some women at risk of developing invasive disease.
Objectives
To assess the optimum management strategy for women with minor cervical cytological abnormalities (atypical squamous cells of
undetermined significance - ASCUS or low-grade squamous intra-epithelial lesions - LSIL) at primary screening in the absence of HPV
(human papillomavirus) DNA test.
Search methods
We searched the following electronic databases: Cochrane Central Register of Controlled Trials (CENTRAL Issue 4, 2016), MEDLINE
(1946 to April week 2 2016) and Embase (1980 to 2016 week 16).
Selection criteria
We included randomised controlled trials (RCTs) comparing immediate colposcopy to cytological surveillance in women with atyp-
ical squamous cells of undetermined significance (ASCUS/borderline) or low-grade squamous intra-epithelial lesions (LSIL/mild
dyskaryosis).
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Data collection and analysis
The primary outcomemeasure studied was the occurrence of cervical intra-epithelial neoplasia (CIN). The secondary outcomemeasures
studied included default rate, clinically significant anxiety and depression, and other self-reported adverse effects.
We classified studies according to period of surveillance, at 6, 12, 24 or 36 months, as well as at 18 months, excluding a possible
exit-examination. We calculated pooled risk ratios (RR) and 95% confidence intervals (CI) using a random-effects model with inverse
variance weighting. Inter-study heterogeneity was assessed with I2 statistics.
Main results
We identified five RCTs with 11,466 participants that fulfilled the inclusion criteria. There were 18 cases of invasive cervical cancer,
seven in the immediate colposcopy and 11 in the cytological surveillance groups, respectively. Although immediate colposcopy detects
CIN2+ and CIN3+ earlier than cytology, the differences were no longer observed at 24 months (CIN2+: 3 studies, 4331 women;
17.9% versus 18.3%, RR 1.14, CI 0.66 to 1.97; CIN3+: 3 studies, 4331 women; 10.3% versus 11.9%, RR 1.02, CI 0.53 to 1.97). The
inter-study heterogeneity was considerable (I2 greater than 90%). Furthermore, the inclusion of the results of the exit examinations
at 24 months, which could inflate the CIN detection rate of cytological surveillance, may have led to study design-derived bias; we
therefore considered the evidence to be of low quality.
When we excluded the exit examination, the detection rate of high-grade lesions at the 18-month follow-up was higher after immediate
colposcopy (CIN2+: 2 studies, 4028 women; 14.3% versus 10.1%, RR 1.50, CI 1.12 to 2.01; CIN3+: 2 studies, 4028 women, 7.8%
versus 6.9%, RR 1.24, CI 0.77 to 1.98) both had substantial inter-study heterogeneity (I2 greater than 60%) and we considered the
evidence to be of moderate quality).
The meta-analysis revealed that immediate referral to colposcopy significantly increased the detection of clinically insignificant cervical
abnormalities, as opposed to repeat cytology after 24 months of surveillance (occurrence of koilocytosis: 2 studies, 656 women; 32%
versus 21%, RR 1.49, 95% CI 1.17 to 1.90; moderate-quality evidence) incidence of any CIN: 2 studies, 656 women; 64% versus
32%, RR 2.02, 95% CI 1.33 to 3.08, low-quality evidence; incidence of CIN1: 2 studies, 656 women; 21% versus 8%, RR 2.58, 95%
CI 1.69 to 3.94, moderate-quality evidence).
Due to differences in trial designs and settings, there was large variation in default rates between the included studies. The risk for
default was higher for the repeat cytology group, with a four-fold increase at 6 months, a six-fold at 12 and a 19-fold at 24 months
(6 months: 3 studies, 5117 women; 6.3% versus 13.3%, RR 3.85, 95% CI 1.27 to 11.63, moderate-quality evidence; 12 months: 3
studies, 5115 women; 6.3% versus 14.8%, RR 6.39, 95% CI 1.49 to 29.29, moderate-quality evidence; 24 months: 3 studies, 4331
women; 0.9% versus 16.1%, RR 19.1, 95% CI 9.02 to 40.43, moderate-quality evidence).
Authors’ conclusions
Based on low- or moderate-quality evidence using the GRADE approach and generally low risk of bias, the detection rate of CIN2+
or CIN3+ after two years does not appear to differ between immediate colposcopy and cytological surveillance in the absence of HPV
testing, although women may default from follow-up. Immediate colposcopy probably leads to earlier detection of high-grade lesions,
but also detects more clinically insignificant low-grade lesions. Colposcopy may therefore be the first choice when good compliance is
not assured. These results emphasize the need for an accurate reflex HPV triage test to distinguish women who need diagnostic follow-
up from those who can return safely to routine recall.
P L A I N L A N G U A G E S U M M A R Y
Management of minor cytological abnormalities identified on cervical screening
The issue
Cervical screening programmes reduce the risk of cervical cancer, through the use of cervical cytology (smear tests), which aim to detect
and treat any precancerous changes which might put some women at risk of developing invasive disease (invasive cervical cancer) in the
future. Usually only severe precancerous changes require treatment, however, there is some discrepancy in how to manage women with
minor cytological changes (atypical squamous cells of undetermined significance (ASCUS/borderline) or low-grade squamous intra-
epithelial lesions (LSIL/mild dyskaryosis) if HPV (human papillomavirus) testing is not routinely available.
The aim of the review
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We aimed to assess whether immediate colposcopy or ’watchful waiting’, with repeat cervical cytology, was better for women with
minor cervical cytological abnormalities.
What are the main findings?
We included 5 randomised controlled trials including 11,466 participants with minor abnormalities on cervical cytology, treated either
with immediate colposcopy or repetitive cytology. The included studies assessed differences in occurrence of cervical precancerous
lesions between the two treatments.
The results suggested that women attending immediate colposcopy after a single low-grade abnormal cervical cytology test were more
likely to have clinically insignificant findings detected than women who were managed with ’watchful waiting’.
There were 18 cases of invasive cervical cancer, seven in the immediate colposcopy and 11 in the cytological surveillance groups. The
detection rate of clinically insignificant low-grade lesions was higher in the immediate colposcopy group, as was the detection rate of
clinically more significant high-grade precancerous lesions (CIN2 or CIN2 or worse) at 18 months, but not by 24 months.
The risk of non-compliance was significantly greater for the repeat cytology arm and increased with the length of the follow-up.
What is the quality of the evidence?
We graded the evidence as low to moderate quality.
What are the conclusions?
HPV DNA testing has been shown to be an effective triage tool for women with minor cervical cytology abnormalities. However, this
test is not currently routinely available globally. Therefore, if HPVDNA testing is not available, immediate colposcopy is likely to detect
more precancerous lesions earlier than cytological surveillance, but after two years there does not seem to be a difference between the
two approaches. Women could be referred for immediate colposcopy after a single low-grade abnormal or borderline cervical cytology
test, if compliance with cytological surveillance is expected to be poor. When follow-up compliance is expected to be good, repeat
cervical cytology may be offered, as this may reduce the risk of over-diagnosis and over-treatment.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Immediate colposcopy compared with cytological surveillance for minor cervical cytological abnormalities: occurrence of different grades CIN in histology according to
follow-up time and default rates
Patient or population: women with ASCUS or LSIL
Settings: colposcopy clinic
Intervention: immediate colposcopy
Comparison: cytological surveillance
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Risk with cytological
surveillance
Risk with immediate
colposcopy
Occurrence of CIN2+ in
histology at 18 months
101 per 1000 151 per 1000
(113 to 203)
RR 1.50 (1.12 to 2.01) 4028
(2 studies)
⊕⊕⊕©
moderate1
Occurrence of CIN2+ in
histology at 24 months
183 per 1000 209 per 1000
(121 to 361)
RR 1.14 (0.66 to 1.97) 4331
(3 studies)
⊕⊕©©
low2,3
Occurrence of CIN3+ in
histology at 18 months
69 per 1000 86 per 1000
(53 to 137)
RR 1.24 (0.77 to 1.98) 4028
(2 studies)
⊕⊕⊕©
moderate4
Occurrence of CIN3+ in
histology at 24 months
119 per 1000 121 per 1000
(63 to 234)
RR 1.02 (0.53 to 1.97) 4331
(3 studies)
⊕⊕©©
low3,5
Occurrence of any CIN
in histology at 24
months
316 per 1000 639 per 1000
(420 to 974)
RR 2.02 (1.33 to 3.08) 656
(2 studies)
⊕⊕©©
low3,8
Default rates at 6
months
63 per 1000 241 per 1000
(80 to 728)
RR 3.85
(1.27 to 11.63)
5117
(3 study)
⊕⊕⊕©
moderate6
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Default rates at 12
months
63 per 1000 413 per 1000
(93 to 1000)
RR 6.60
(1.49 to 29.29
5115
(3 studies)
⊕⊕⊕©
moderate7
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI). For default rates the relat ive ef fect is calculated between
cytological surveillance versus immediate colposcopy. For histology the relat ive ef fect is calculated between immediate colposcopy versus cytological surveillance.
ASCUS: atypical squamous cells of undeterm ined signif icance CI: Conf idence interval; CIN: cervical intraepithelial neoplasia; LSIL: low-grade squamous intra-epithelial lesions;
RR: Risk Ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded to moderate due to substant ial inter-study heterogeneity (P = 0.08, I2= 61%).
2 Downgraded to low due to considerable inter-study heterogeneity (P < 0.00001, I2= 94%).
3 Downgraded due to presence of the other possible bias result ing in falsely high CIN detect ion rate in the cytological
surveillance arm.
4 Downgraded to moderate due to substant ial inter-study heterogeneity (P = 0.02, I2= 75%).
5 Downgraded to low due to considerable inter-study heterogeneity (P < 0.00001, I2= 93%).
6 Downgraded to moderate due to considerable inter-study heterogeneity (P = 0.02, I2= 76%).
7 Downgraded to moderate due to considerable inter-study heterogeneity (P = 0.0004, I2= 87%).
8 Downgraded to low due to substant ial inter-study heterogeneity (P = 0.02, I2 = 82%).
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B A C K G R O U N D
Cervical cancer is largely preventable through screening and treat-
ment of screen-detected cervical lesions. Despite this, cervical can-
cer remains the most common female malignancy in virtually all
low- and middle-income countries, and the third most common
inwomenworldwide (GLOBOCAN 2013).Of all cervical cancer,
83% occurs in low-income countries. Cervical cancer still remains
an important public health issue in Europe withmore than 66,000
new cases and 29,000 deaths annually. The majority of these cases
are diagnosed in Eastern European countries, which reflects the
absence of a screening programme (Arbyn 2007). A woman’s risk
of developing cervical cancer by age 75 years ranges from 0.9% in
high-income countries to 1.9% in low- and middle-income coun-
tries (Arbyn 2011). In Europe, about 60% of women with cervi-
cal cancer are alive five years after diagnosis (EUROCARE 2003).
The disease primarily affects younger women and therefore, the
total years-of-life lost is proportionately higher than that for most
other cancers, which often have a later onset.
The purpose of cervical cytology screening programmes using cy-
tology (also known as Pap smear, named after Dr Papanicolaou
(Papanicolaou 1941), is the early detection and treatment of pre-
invasive lesions and, ultimately, reduction in both the incidence
and mortality from cervical cancer. Screening programmes have
proven their value and efficacy in reducing both the incidence and
mortality from cervical cancer in countries where they have been
widely applied, including the UK. In countries with an established
screening programme, there are different challenges: improving
coverage and accuracy of screening, as well as the selection and
better management of women with lesions of true malignant po-
tential that require intervention. Without doubt, the most signif-
icant advance globally has been the realisation that persistent in-
fection with oncogenic human papillomavirus (HPV) is causally
associated with cervical cancer, as well as the development of pro-
phylactic vaccines. The HPV DNA test that aims to detect the
viral genome has also been developed and has potential clinical
applications in primary screening, in the triage of minor cytolog-
ical abnormalities, and in follow-up after treatment (Arbyn 2004;
Bulkmans 2007; Koliopoulos 2007; Naucler 2007; Paraskevaidis
2004).
Description of the condition
Cervical cytology may be classified according to the Bethesda sys-
tem (Solomon 2002), or the British Society of Cervical Cytology
(BSCC) terminology (NHSCSP 2000), and can be reported in
order of severity as: (1) normal; (2) atypical squamous cells of un-
determined significance (ASCUS) (Bethesda)/borderline (BSCC);
(3) low-grade squamous intra-epithelial lesion (LSIL) (Bethesda)/
mild dyskaryosis (BSCC); (4) high-grade squamous intraepithelial
lesion (HSIL) (Bethesda)/high-grade dyskaryosis (either favours
moderate or severe) (BSCC). Cervical cytology classified as high-
grade (moderate and severe dyskaryosis in the UK) occurs in
roughly 1% to 3% of the screened population. A high-grade le-
sion (cervical intra-epithelial neoplasia 2+ (CIN2+)) is confirmed
by histology in greater than 50% to 60% of these cases. The risk
of subsequent progression to malignancy is approximately 30%,
although a significant proportion (20% to 30%) have regressive
CIN.
Although it is widely accepted that women with high grade cyto-
logical abnormalities should be referred immediately for a colpo-
scopic examination or subsequent treatment, or both, uncertainty
exists regarding the optimum way of managing those with low-
grade findings.
Women with cytology classified as ASCUS or LSIL (Bethesda
classification) (Solomon 2002), or their British Society of Cervical
Cytology (BSCC) terminology (NHSCSP 2000) equivalents of
borderline and mild dyskaryosis, comprise approximately 7% of
all the smears performed in the UK every year (Department of
Health 2006). These minor abnormalities, with unknown or low
malignant potential, are more common in younger women and
present a difficult problem with regards to their management; the
implications are important as they consume a disproportionate
amount of clinical resources, with their significance still debatable.
However, despite a low-grade cytological smear, a considerable
proportion of these women (15% to 20%) still have an underlying
histological high-grade lesion (CIN2+) (Bolger 1988; Contreras-
Melendez 1992; Flannelly 1997; Giles 1989; Paraskevaidis 2002;
Soutter 1986;Walker 1986) and therefore, are at risk of developing
invasive disease.
The HPV test appears to have a role in the triage of those women
who need referral to colposcopy. Evidence in the literature reports
a significantly better sensitivity and similar specificity for the HPV
test in comparison to repeat cytology for the detection of high-
grade lesions for initial ASCUS/borderline cytology (55% pos-
itivity). The introduction of the HPV DNA test in cases with
ASCUS cytologic findings could enhance the detection of those
women with underlying high-grade CIN who should be referred
to colposcopy or returned to routine recall instead of repeat cy-
tology (Arbyn 2004; Arbyn 2012; Kelly 2011). A survey amongst
43 European countries in 2013 showed that the majority (90%)
of the countries have introduced HPV testing for ASCUS triage,
and 62% use the test in the triage of LSIL as well (Arbyn 2015).
However, this does not appear to be true for LSIL/mild dyskaryosis
lesions orwomenunder 30 to40 years, as the high-positivity rate of
HPV in this group (85%), does not support its use as a triage tool
(Arbyn 2005; Arbyn 2013a; TOMBOLA 2009). Furthermore the
HPV test is not yet widely available, reinforcing the need for clear
recommendations in settings without access to these triage tests
(Cuzick 2008).
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Description of the intervention
Until new, markedly reliable triage markers develop, the manage-
ment options of LSIL cytology remain either immediate referral
to colposcopy (examination of the cervix and vagina using magni-
fying light microscope, colposcope, and acetic acid) or cytological
surveillance with repeat smears.
A repeat cytology sample at six months may identify women with
persistent lesions who require referral to colposcopy.
The management after immediate referral to colposcopy will de-
pend on the colposcopic findings. If they are suggestive of a high-
grade lesion, multiple punch biopsies may be appropriate, par-
ticularly in young women of reproductive age. If the colposcopic
findings are consistent with a low-grade lesion, surveillance every
six months and treatment, only if the abnormality persists beyond
two years, may be justified, particularly in young women, as a
significant proportion of these lesions may regress. The rate of
regression decreases significantly with increasing age, and in the
presence of a high-risk HPV subtype and increasing duration of
presence of the lesion (Kyrgiou 2010).
How the intervention might work
Optimising management of women with LSIL cervical cytology
is difficult.
A policy of immediate referral to colposcopy could potentially re-
sult, not only in increased numbers of referrals, thus overloading
colposcopy clinics and increasing costs, but also in over-interven-
tion or over-treatment, or both, due to subtle colposcopic find-
ings. Many young women of reproductive age might be exposed
to the physical and psychological sequelae of unnecessary inter-
ventions and treatment, which can also be associated with long-
term, pregnancy-related, morbidity (Arbyn 2008; Founta 2010;
Kyrgiou 2006; Kyrgiou 2012a; Kyrgiou 2014; Kyrgiou 2016a;
Paraskevaidis 2007).
On the other hand, triage with repeat cytology, and referral to col-
poscopy, only if the abnormality persists, may result in a potential
reduction of the number of unnecessary referrals, but carries risks
of missing high-grade lesions and increased non-attendance rates
(Shafi 1997). Default from screening is known to put women with
equivocal smears and occult high-grade disease at risk of develop-
ing invasive cancer.
The TOMBOLA study in the UK showed that, compared with
cytological surveillance, a policy of immediate colposcopy does
detect more high-grade lesions, but might lead to over-treatment.
To reduce this, the trial authors suggested that a policy of targeted
punch biopsies with subsequent treatment for CIN2 and CIN3,
and cytological surveillance for CIN1 or less, provides the best
balance between benefit and harm for the management of these
women. Immediate loop excision resulted in over-treatment and
more adverse effects, and was therefore not be recommended (
TOMBOLA 2009).
Why it is important to do this review
This review aimed to appraise the current evidence from RCTs
on cytological surveillance versus immediate colposcopy in the
absence of HPV-testing in order to make a decision on optimum
evidence based practice, as currently this is an area of uncertainty.
A list of abbreviations used in the text can be found in Appendix
1.
O B J E C T I V E S
To assess the optimum management strategy for women with mi-
nor cervical cytological abnormalities (atypical squamous cells of
undetermined significance - ASCUS or low-grade squamous in-
tra-epithelial lesions - LSIL) at primary screening in the absence
of HPV (human papillomavirus) DNA test.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all RCTs comparing immediate referral to colposcopy
versus cytological surveillance in women with ASCUS or LSIL
cytological abnormalities at primary cervical screening in the ab-
sence of HPV DNA testing. We only included studies reporting
combined data for minor abnormalities with more severe grades
(high-grade SIL, moderate and severe dyskaryosis), if separate data
according to the grade were available. In case of overlap or dupli-
cate reports, we extracted all relevant outcomes from all the pub-
lications of each trial. We included trials with multiple arms if at
least two arms addressed an eligible comparison; non-eligible arms
were excluded. We excluded non-randomised studies and pseudo-
randomised trials with alternate allocation of subjects; meeting
and conference abstracts; and studies comparing HPV DNA test
to colposcopy or repeat cytology.
Types of participants
We included studies with adult women (greater than 18 years old)
with minor cytological cervical abnormalities (ASCUS/borderline
dyskaryosis and LSIL/mild dyskaryosis). From included studies
we excluded women with high-grade squamous intra-epithelial
lesions (HSIL)/moderate and severe dyskaryosis, when separate
data for LSIL abnormalities were available.
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Types of interventions
Surveillance with repeat cytology in any setting versus immediate
colposcopy.
The gold standard was histological diagnosis at colposcopy or at
the end of the surveillance period in the form of punch biopsies or
excisional treatment. Excisional treatment included large loop ex-
cision of the transformation zone (LLETZ or LEEP), laser coniza-
tion (LC), cold knife conization (CKC) and needle or straight
wire excision of the transformation zone (NETZ/SWETZ). We
excluded trials that did not report on histological results (gold
standard) (for example, in the form of punch biopsies or excisional
treatment).
Types of outcome measures
Primary outcomes
The primary outcomes were the cumulative incidence of cervical
intra-epithelial neoplasia grade 2 or worse (CIN2+) and grade 3
or worse (CIN3+) from histology assessment.
Secondary outcomes
The secondary outcomes included:
• cumulative incidence at other histological thresholds,
including HPV-associated morphological findings and CIN1;
• default rates from repeat cytology or colposcopy clinic
appointments;
• anxiety and depression scores (based on validated
questionnaires);
• short-term adverse effects of management (pain, bleeding,
and discharge, together with the duration (in days) and severity;
and
• treatment rates in both groups.
Search methods for identification of studies
We searched for papers in all languages.
We searched the literature from1946,when the conservativemeth-
ods of treatment for CIN were first introduced into clinical prac-
tice, and included references published up to the present day.
We identified the RCTs comparing these alternative strategies for
the management of low-grade cervical abnormalities by a com-
puterised literature search, by tracing references listed in relevant
articles and by a manual search of appropriate journals.
Electronic searches
See: Cochrane Gynaecological Cancer Groupmethods used in re-
views.
We searched the following electronic databases.
• The Cochrane Central Register of Controlled Trials
(CENTRAL, 2016, Issue 4)
• MEDLINE (Ovid) (1946 to April week 2, 2016)
• Embase (Ovid) (1980 to 2016, week 16)
We used the following main keywords: ‘randomised controlled
trials’ ‘cervical intraepithelial neoplasia (CIN)’, ‘cervical cancer’,
‘ASCUS’, ‘borderline’, ‘LSIL’, ‘low-grade squamous intra-epithe-
lial lesion’, ‘mild dyskaryosis’, ‘colposcopy’, ‘smear’, ‘cytology’.
We used the ’related articles’ feature in MEDLINE to retrieve
additional references. For databases other than MEDLINE, we
adapted the search strategy accordingly. The search strategies for
all the databases are available in Appendix 2, Appendix 3 and
Appendix 4.
Searching other resources
We searched the metaRegister of
controlled trials (www.isrctn.com/page/mrct), the National Can-
cer Institute’s database (www.cancer.gov/clinicaltrials), Physicians
Data Query (www.cancer.gov/publications/pdq), Current Con-
trolled Trials (www.controlled-trials.com), and ClinicalTrials.gov
(www.clinicaltrials.gov) for ongoing studies.
We searched conference proceedings and abstracts through Zetoc
(http://zetoc.mimas.ac.uk) and WorldCat
Dissertations (www.oclc.org/support/documentation/firstsearch/
databases/dbdetails/details/WorldCatDissertations.htm). We also
searched reports of conferences in the following sources.
• Annual Meetings of the British Society of Colposcopy and
Cervical Pathology.
• Triannual Meetings of the International Federation of
Cervical Pathology and Colposcopy.
• Triannual Meetings of the European Federation of
Colposcopy.
• Annual Meetings of the American Society of Colposcopy
and Cervical Pathology.
We checked the citation lists of included studies and contacted
experts in the field, Presidents of the British, European, American
and International Societies of Colposcopy and Cervical Pathology
to identify further reports of studies.
We intended to include both published and unpublished studies,
if they met the inclusion criteria for the review.
Data collection and analysis
Selection of studies
We downloaded all titles and abstracts retrieved by electronic
searching into the reference management database Endnote. We
removed duplicates and two review authors (MK, IK) indepen-
dently examined the remaining references. We excluded those tri-
als which clearly did not meet the inclusion criteria, and obtained
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copies of the full text of potentially relevant references. We (MK,
IK) independently assessed the eligibility of the retrieved papers.
We then compared the results and resolved any disagreements by
discussion. If necessary, we involved a third review author (MA)
to reach consensus. We documented the reasons for exclusion.
Data extraction and management
We (MK, IK) extracted the relevant data from the trials identified.
This included study population, population characteristics, sam-
ple size, study methods, method of randomisation, methodologi-
cal quality, follow-up and dropout, assessment of outcomes, and
results).
We classified trials according to the length of cytological surveil-
lance (6, 12, 18, 24, 30, and 36 months) and analysed them in
different groups.
We extracted or computed from all included studies, the total
number of women included and incidence of all grades of histo-
logical diagnoses, default rates, depression, anxiety scores, after-ef-
fects and other patient-reported outcomes in both groups, when-
ever available. We contacted trial authors to obtain separate data
when data on LSILs were merged with HSIL lesions.
In addition, we collected data on the length of period of surveil-
lance and the type of histology used at the end of surveillance or
at colposcopy (gold standard: punch biopsies or excisional treat-
ment).
We also documented the diagnostic criteria used for the interpre-
tation of cytology and histology in each study, where these were
read, and whether there was a central review in each study in or-
der to assess if the above had significant variation that may have
impacted on the value of the review.
For included trials, we extracted the following data.
• Author, year of publication, journal and language
• Country
• Setting where the trial was conducted
• Inclusion and exclusion criteria
• Trial design, methodology
• Trial population
◦ total number enrolled and number included in each
group
◦ participant characteristics (such as age and other
demographic and socioeconomic characteristics - risk factors for
cervical cancer)
◦ index cytology, history of previous cytological lesions
◦ type of cytology (conventional or liquid-based)
• Intervention details
◦ surveillance with repeat cytology in primary care and
number of follow-up smears
◦ immediate colposcopy and related interventions (i.e.
punch biopsies and/or treatment and type)
◦ the type of gold standard used (histology at colposcopy
or at the end of the surveillance period): punch biopsies or
excisional treatment. We planned to report the type of excisional
treatment: LLETZ or LEEP, LC, CKC and NETZ or SWETZ.
• Risk of bias (See Assessment of risk of bias in included
studies)
• Outcomes reported in each trial
◦ Primary outcomes:
the cumulative incidence of CIN2+ and CIN3+
at histology
◦ Secondary outcomes:
⋄ cumulative incidence at other histological
thresholds HPV-associated morphological findings and CIN1
⋄ default rates from repeat cytology or colposcopy
clinic appointments
⋄ treatment rates in both groups
⋄ anxiety scores
⋄ depression scores
⋄ short-term after-effects of management (rates and
types), specifically pain, bleeding, and discharge, together with
the duration (in number of days) and severity
⋄ other self-reported outcomes
◦ Details of outcomes reported:
⋄ for each outcome: outcome definition (with
diagnostic criteria if relevant)
⋄ unit of measurement (if relevant)
⋄ for scales: upper and lower limits, and whether
high or low score is good
⋄ results: number of participants allocated to each
intervention group
⋄ for each outcome of interest: sample size; missing
participants
⋄ the time points at which outcomes were collected
and reported
We extracted data on outcomes as below.
• For dichotomous outcomes (all outcomes were reported as
dichotomous), we extracted the number of women in each
treatment arm who experienced the outcome of interest and the
number of women assessed at endpoint, in order to estimate a
risk ratio (RR).
We (MK, IK) independently extracted data in a data extraction
form specially designed for the review. We resolved differences
between review authors by discussion or by appeal to a third review
author (MA), if necessary.
Assessment of risk of bias in included studies
We used the Cochrane tool for assessing risk of bias (Higgins
2011).We (MK, IK) independently assessed the risk of bias within
each included study based on the following six domains, with our
judgements presented as ’low risk of bias’; ’high risk of bias’, and
’unclear’.
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For RCTs, if identified, we included assessment of:
• sequence generation;
• allocation concealment;
• blinding (of participants, healthcare providers and outcome
assessors);
• incomplete outcome data:
◦ we recorded the proportion of participants whose
outcomes were not reported at the end of the study; we noted if
loss to follow-up was not reported. We coded the satisfactory
level of loss to follow-up for each outcome as:
⋄ ’low risk of bias’, if fewer than 20% of
participants were lost to follow-up, and reasons for loss to follow-
up were similar in both treatment arms
⋄ ’high risk of bias’, if more than 20% of
participants were lost to follow-up, or reasons for loss to follow-
up differed between treatment arms
⋄ ’unclear’ if loss to follow-up was not reported;
• selective reporting of outcomes; and
• other possible sources of bias.
Measures of treatment effect
For all (dichotomous) outcomes, we used the risk ratio (RR).
Dealing with missing data
We contacted one study author to obtain data stratified by grade
of index cytology (Flannelly 1994). Otherwise, all relevant data
were available from the original publications. We did not impute
any missing outcome data.
Assessment of heterogeneity
We assessed inter-study heterogeneity with the Cochran Q test
(Cochran 1954), by visual inspection of forest plots (Deeks 2011),
by estimation of the percentage of heterogeneity between stud-
ies which cannot be ascribed to sampling variation (I2 statistic)
(Higgins 2003), and by a formal test of the significance for het-
erogeneity (Deeks 2001). If there was evidence of substantial het-
erogeneity, we investigated and reported the possible reasons for
it.
Assessment of reporting biases
We explored potential publication bias graphically in the funnel
plot (Sterne 2011).
Data synthesis
When sufficient clinically similar studies were available, we pooled
their results inmeta-analyses.We calculated the risk ratio (RR) and
95% confidence intervals (95% CI) for each reported outcome in
the immediate colposcopy versus repeat cytology arm for dichoto-
mous outcomes using the Cochrane Review Manager 5 software
(RevMan 2014).Weused random-effectsmodelswith inverse vari-
ance weighting for all meta-analyses (Dersimonian 1986). If data
were not of suitable quality for meta-analysis, we presented the
data in tables and discussed the data in the text of the review. We
analysed data according to different lengths of surveillance: 6, 12,
18, 24, 30, 36 or more months.
Subgroup analysis and investigation of heterogeneity
We performed a subgroup analysis and analysed the data sepa-
rately for ASCUS/borderline and LSIL/mild dyskaryosis smears,
wherever possible.
Sensitivity analysis
We performed a sensitivity analysis excluding one trial (ALTS
2003) that showed opposite evidence compared to other included
studies. No additional sensitivity or subgroup analyses were pos-
sible due to the small number of studies in each meta-analysis.
Quality of evidence
We presented the overall quality of the evidence for each outcome
according to the GRADE approach, which takes into account is-
sues not only related to internal validity (risk of bias, inconsistency,
imprecision, publication bias) but also to external validity such as
directness of results (Langendam 2013). We created a ’Summary
of findings’ table based on the methods described the Cochrane
Handbook for Systematic Reviews of Interventions (Schünemann
2011) and using GRADEpro GDT.We used the GRADE check-
list and GRADE Working Group quality of evidence definitions
(Meader 2014).
• High quality: Further research is very unlikely to change
our confidence in the estimate of effect.
• Moderate quality: Further research is likely to have an
important impact on our confidence in the estimate of effect and
may change the estimate.
• Low quality: Further research is very likely to have an
important impact on our confidence in the estimate of effect and
is likely to change the estimate.
• Very low quality:We are very uncertain about the estimate.
R E S U L T S
Description of studies
The characteristics of the included and excluded studies and
the outcomes examined are described in the Characteristics of
included studies and Characteristics of excluded studies tables.
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Results of the search
The searches identified 5176 records (4715 after de-duplication).
We screened the abstracts and excluded 4699 records. We iden-
tified 16 potentially eligible full-text articles for further assess-
ment. We did not identify any unpublished studies. Altogether
eight of the 16 identified full-text articles were supporting re-
ports of the same large trial (TOMBOLA 2009) and two full-text
articles reported the same outcomes for one trial (ALTS 2003),
but separately, depending on the initial histology of ASCUS or
LSIL. We excluded a further two studies after full text review:
one that was not a RCT (De Bie 2011), and one study that did
not report required outcomes (Elit 2011). After combinations and
exclusions, five unique studies fulfilled the inclusion criteria of
this review (ALTS 2003; Flannelly 1994; Kitchener 2004; Shafi
1997; TOMBOLA2009).More details of the literature search and
the reasons for exclusion are presented in the PRISMA flowchart
(Moher 2009) (Figure 1).
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Figure 1. Study flow diagram
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Included studies
The detailed characteristics of the included studies are shown
in Characteristics of included studies and individual outcomes
in Table 1. The five studies included 11,466 participants. All
studies were , one conducted in the USA (ALTS 2003) and
four in the UK (Flannelly 1994; Kitchener 2004; Shafi 1997;
TOMBOLA 2009). Four studies explored the two management
strategies in women with either ASCUS (borderline) or LSIL
(mild dyskaryosis) (ALTS 2003; Kitchener 2004; Shafi 1997;
TOMBOLA 2009), and one study looked at women with mild
or moderate dyskaryosis (Flannelly 1994). We obtained separate
data for women referred with mild or moderate dyskaryosis from
the study authors (Flannelly 1994) and only included women
with mild dyskaryosis in the analysis. All studies assessed non-at-
tendance and the rates for different CIN grades at histology for
the immediate colposcopy group, as compared to the histologi-
cal diagnosis at the end of the surveillance period. Two studies
(Kitchener 2004; TOMBOLA 2009) assessed the psychological
morbidity of the different approaches (i.e. anxiety, depression and
other self-reported outcomes). The length of the surveillance pe-
riod varied between studies. Three of the included RCTs followed
up women for up to 24 months (ALTS 2003; Flannelly 1994;
Shafi 1997), one for 12 months (Kitchener 2004) and another
for 36 months (TOMBOLA 2009). One study had four arms
with different lengths of follow-up (immediate colposcopy versus
surveillance for 6, 12, or 24months) (Flannelly 1994). Three stud-
ies provided interim histological results (ALTS 2003; Shafi 1997;
TOMBOLA 2009), while two of the studies provided results only
at the end of the surveillance period (Flannelly 1994; Kitchener
2004). The largest trial randomised 5060 women (ALTS 2003)
and the smallest 353 (Shafi 1997).
The design,management protocol and exit examination somewhat
varied for different studies. Flannelly 1994 randomly allocated
women into four groups: immediate colposcopy, or 6, 12 and 24
months’ surveillance. All recruited women underwent LLETZ at
the conclusion of their study arm that was preceded by a directed
punch biopsy, if a distinct lesion was seen. Women were with-
drawn if there were severe cytological abnormalities or colposcopic
impression of possible microinvasion. Shafi 1997 had a similar de-
sign and treated all women immediately on the day of recruitment
or at the completion of 24 months of surveillance. Women were
treated during follow-up, if the follow-up smear showed severe
dyskaryosis or worse.
Kitchener 2004 had a different design and randomised women
into two principal groups: cytological surveillance for 12 months
(with colposcopy and treatmentwhen necessary at 6 or 12months,
if either follow-up smear was abnormal) versus the choice to have
surveillance or immediate colposcopy and treatment when nec-
essary. Results on attendance rates were presented for 6 and 12
months’ surveillance. In TOMBOLA 2009 (the Trial Of Man-
agement of Borderline and Other Low grade Abnormal smears)
women were followed up at 6-month intervals for 36 months
in the cytological surveillance arm. The follow-up, as well as the
immediate colposcopy, were done within a routine nationwide
healthcare practice. Moderate dyskaryosis or worse, or three con-
secutive inadequate results led to referral to colposcopy, whereas
women who reverted to normal were discharged to “routine 3-
yearly recall” after three consecutive normal smears. Women allo-
cated to immediate colposcopy were further randomised to either
immediate treatment (LLETZ) or directed biopsies with selective
recall for treatment, if the colposcopy was adequate and showed
abnormalities (no additional procedures were carried out if the
colposcopy was normal). Women from both arms were recalled
for exit examination at 36 months that included colposcopy and
LLETZ if the transformation zone was abnormal.
In the ALTS 2003 (ASCUS-LSIL Triage Study) trial, all women
after randomisation had a repeat liquid-based cytology sample
(LBC) for cytology and HPV testing at enrolment. Women in the
cytological surveillance arm were followed up for 24 months at
6-month intervals with pelvic examination, cervical smear, HPV-
test and cervicography taken at each visit. If the cytology suggested
HSIL or worse at enrolment or during surveillance, women were
referred to colposcopy with treatment if CIN2 or worse was de-
tected on a biopsy. The immediate-colposcopy-arm women un-
derwent a colposcopic examination on the same day or within 3
weeks from recruitment and received treatment if CIN2 or 3 was
detected at biopsy. Women from both arms were recalled for exit
colposcopy at 24 months; treatment was performed if CIN2 or 3
was detected on biopsy and for women with CIN1 with history
of LSIL or HPV+ ASCUS during at least one of the previous two
visits.
Excluded studies
Studies excluded during full-text review are described in the
Characteristics of excluded studies table. The reasons for exclusion
were non-randomised design in one (De Bie 2011) and in one
study the exposure of interest was low-grade histological changes
(CIN1 to 2) instead of cytological changes (Elit 2011).
Risk of bias in included studies
Generally we considered the risk of selection and reporting biases
across included trials to be low. The risk of performance bias and
other possible sources of bias we considered high in all included
trials. Risk of detection bias (TOMBOLA 2009), as well as attri-
tion bias (ALTS 2003) were each considered low in only one trial.
We have presented the quality assessment of the included RCTs
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with the Cochrane tool in Risk of bias in included studies and in
Figure 2.
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
14Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
(Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation
We considered the random sequence generation appropriate in
all studies and the allocation concealment in all but one study
(Flannelly 1994), which did not describe the allocation conceal-
ment process in full.
Blinding
Blinding of participants and personnel was not possible given the
nature of the intervention. There was no blinding of the outcome
in two studies (Kitchener 2004; Shafi 1997), while the risk of
detection bias was low in TOMBOLA 2009 and unclear in the
remaining studies (ALTS 2003; Flannelly 1994). Kitchener 2004
and Shafi 1997 stated that the outcome assessors were not blinded.
Flannelly 1994 described no details of the blinding. ALTS 2003
reported that all clinical information were unmasked during the
exit examination, but included no description of the blinding of
the assessors during the follow-up period. TOMBOLA 2009 de-
scribed that the colposcopists performing the exit examination
were blinded to the initial cytology results, the randomisation arm
and the clinical events that occurred after randomisation, although
it is unclear whether the personnel were blinded during surveil-
lance.
Incomplete outcome data
Loss to follow-up rates were high overall. The highest rates were
seen in Kitchener 2004 and TOMBOLA 2009 (23% and 42%
respectively), while the impact was judged as unclear in another
two (Flannelly 1994; Shafi 1997). ALTS 2003 had the lowest rates
of losses to follow-up (14% to 17%).
Selective reporting
We considered the risk of selective reporting low in all trials, al-
though only TOMBOLA 2009 and ALTS 2003 had pre published
protocols.
Other potential sources of bias
Other potential sources of bias were considered to be high in all tri-
als. One trial used Zelen randomisation, where participants them-
selves in one randomisation group (choice-group) chose whether
they preferred an immediate colposcopy or cytological surveil-
lance, which might have created bias towards either direction in
terms of later incidence of CIN2+ or CIN3+ lesions (Kitchener
2004). All other trials included either a deferred treatment (Shafi
1997), a colposcopy in addition to cytological surveillance on all
follow-up visits (Flannelly 1994) or had an exit examination with
colposcopy regardless of the results of the cytological surveillance
at the end of trial (ALTS 2003; TOMBOLA 2009). This could
well have introduced detection bias and over inflated the CIN de-
tection rate in the cytological surveillance arms. We further ac-
counted for this possible source of bias by presenting and meta-
analysing the results without the exit-examination when possible
(18-month follow-up window).
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings: occurrence of CIN and default rates
Primary outcomes
Occurrence of CIN2+
In themajority of the included studies that presented data onmore
than one time point (ALTS 2003; Flannelly 1994; Shafi 1997;
TOMBOLA 2009), the incidence of CIN2+ was higher for the
immediate colposcopy group at the first time point (before the exit
examination at the time of completion), but showed no difference
with time (at the time of the trial’s completion) (Table 1). Flannelly
1994 revealed differences between the intervention groups for all
time points assessed.
The meta-analysis at 18 months (without the exit examination)
revealed a difference in the detection of CIN2+ between the two
groups (14.3%versus 10.0%,RR1.50,CI 1.12 to 2.01) with some
heterogeneity (P = 0.08, I2 = 61%), (moderate-quality evidence).
There was no difference at 24 months (17.9% versus 18.3%, RR
1.14, 95% CI 0.66 to 1.97), but there was high inter-study het-
erogeneity (P < 0.00001, I2 = 94%) and presence of other possible
bias, resulting in a falsely high CIN detection rate in the cytologi-
cal surveillance arm, and we considered this to be low-quality ev-
idence (Analysis 1.1; Figure 3; Summary of findings for the main
comparison).
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Figure 3. Forest plot of comparison: occurrence of CIN2+ at different lengths of follow-up
Occurrence of CIN3+
All the studies assessed the detection rate of CIN3 or worse
(CIN3+), although the time point assessed varied. The studies
showed conflicting results, as some studies showed an increase in
theCIN3+detectionwith immediate colposcopy (Flannelly 1994;
Kitchener 2004), one found improved detection at 18 months
(without the exit examination) but not at 24months (Shafi 1997),
TOMBOLA 2009 found no difference, while ALTS 2003 found
no difference at 18 months (without the exit examination), and
a higher CIN3+ detection rate for cytological surveillance at 24
months (Table 1).
The cumulative incidence of CIN3+ was increased after immedi-
ate colposcopy when compared to cytological surveillance at 12
months (32% versus 14.0%, RR 2.07, 95% CI 1.54 to 2.79, P =
0.41, I2 = 0%), but due to other possible bias resulted in a falsely
high CIN detection rate in the cytological surveillance arm, al-
though at 18 months (without the exit examination) (7.8% versus
6.9%, (moderate-quality evidence), 95% CI 0.77 to 1.98) and
24 months (10.3% versus 11.9%, RR 1.02, CI 0.53 to 1.97),
this difference was no longer observed. This was mainly driven by
the opposing results of a large trial (ALTS 2003). There was high
inter-study heterogeneity for the comparison at 18 months (P <
0.02, I2 = 75%) (moderate-quality evidence), and at 24 months
(P < 0.00001, I2 = 93%). In addition to high heterogeneity the
presence of other possible bias probably resulting in a falsely high
CIN detection rate in the cytological surveillance arm, meant that
we regarded this as low-quality evidence (Analysis 2.1; Figure 4;
Summary of findings for the main comparison).
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Figure 4. Forest plot of comparison: occurence of CIN3+ at different lengths of follow-up
Secondary outcomes
Incidence of other CIN grades at histology
Occurrence of histologically proven HPV or koilocytic atypia
One study assessed this at 6, 12 and 24 months (Flannelly 1994)
and another at 24 months of surveillance (Shafi 1997). Flannelly
1994 reported a lower rate of HPV-associated histological changes
for immediate colposcopy as compared to six-month cytological
surveillance (9% versus 17%, RR 0.52, 95% CI 0.28 to 0.95) but
no difference was observed at 12 or 24 months. Interestingly, Shafi
1997 identified a higher rate for women attending for immediate
colposcopy, as opposed to repeat cytology (50.5% versus 33.3%,
RR 1.52, 95% CI 1.17 to 1.96) (Table 1).
The meta-analysis revealed that immediate referral to colposcopy
increased the detection of clinically non-significant infections as
opposed to repeat cytology at 24 months (32% versus 21%, RR
1.49, 95% CI 1.17 to 1.90) (Analysis 4.1). There was no evident
inter-study heterogeneity (P = 0.69, I2 = 0%), but due to other
possible bias resulting in a falsely high CIN detection rate in the
cytological surveillance arm, we regarded this as moderate-quality
evidence.
Occurrence of any CIN
Three studies provided data on the rates of any CIN grade
(Flannelly 1994; Kitchener 2004; Shafi 1997). Flannelly 1994
provided data for cytological surveillance at 6, 12 and 24 months,
Kitchener 2004 at 12 months and Shafi 1997 at 24 months. All
individual studies demonstrated that women undergoing imme-
diate colposcopy had a higher rate of detected CIN of any grade
(Table 1).
The meta-analysis confirmed that the cumulative incidence of any
grade of CINwas higher amongwomen referred to immediate col-
poscopy (12 months: RR 1.72, 95% CI 1.09 to 2.70; 24 months:
RR 2.02, 95% CI 1.33 to 3.08). Considerable heterogeneity was
present at both time points (P = 0.001, I2 = 91% and P = 0.02, I
2 = 82%, respectively) and due to other possible bias resulting in
falsely highCINdetection rates in the cytological surveillance arm,
we regarded this as low-quality evidence (Analysis 3.1; Analysis
4.1; Summary of findings for the main comparison).
Occurrence of CIN1
One study that assessed the rate of CIN1 at six and 12 months
suggested no difference between immediate colposcopy and cy-
tological surveillance (Flannelly 1994) (Table 1). Two studies as-
sessed the occurrence of CIN1 rate at 24 months (Flannelly 1994;
Shafi 1997), both of which suggested a higher rate of detection of
low-grade disease in the immediate colposcopy group (Table 1).
The meta-analysis revealed at least double the rate of CIN1 detec-
tion when women underwent colposcopy immediately as opposed
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to repeat cytology (21% versus 8%, RR 2.58, 95% CI 1.69 to
3.94), suggesting that immediate colposcopy may have increased
the detectionof clinically insignificant lesions (Analysis 4.1). There
was no evident inter-study heterogeneity (P = 0.81, I2 = 0%), but
due to other possible bias resulting in a falsely high CIN detection
rate in the cytological surveillance arm we regarded this as mod-
erate-quality evidence.
Occurrence of CIN2
Four studies assessed the incidence of CIN2 (ALTS 2003;
Flannelly 1994; Shafi 1997; TOMBOLA 2009); one reported re-
sults at 6 and 12 months (Flannelly 1994), two (ALTS 2003;
Shafi 1997) at 18 months (without the exit examination), three
(ALTS 2003; Flannelly 1994; Shafi 1997) at 24 months and one
(TOMBOLA 2009) at 30 and 36 months. The rate of CIN2 was
higher in the immediate colposcopy group in the majority of the
studies, apart from one (Shafi 1997). The difference in CIN2 rate
detection was higher at 18 months rather than at 24 months in
ALTS 2003 and similarly at 30 months as opposed to 36 months
in TOMBOLA 2009 (Table 1).
The overall rate of CIN2 in the meta-analysis was higher for the
immediate colposcopy group at 18 months (6.5% versus 3.2%,
RR 2.04, CI 1.52 to 2.73) with low heterogeneity (P = 0.46, I
2= 0%); high-quality evidence (Analysis 5.1; Figure 5). There was
no evident difference at 24 months of surveillance (7.6% versus
5.4%, RR 1.45, 95% CI 0.87 to 2.40); there was considerable
inter-study heterogeneity (P = 0.009, I2= 74%), and additionally,
due to the presence of other possible bias resulting in a falsely high
CIN detection rate in the cytological surveillance arm, this was
regarded as low-quality evidence.
Figure 5. Forest plot of comparison: occurence of CIN2 at different lengths of follow-up
In total there were 18 cases of invasive cervical cancer, seven in
immediate colposcopy and 11 in cytological surveillance groups:
one case of stage 1A1 cervical cancer in the deferred treatment
group detected by cytological smear in Shafi 1997, three cases of
invasive cervical cancer in both immediate colposcopy and cyto-
logical surveillance groups in ALTS 2003 and four cases of inva-
sive disease in immediate colposcopy and seven in the cytological
surveillance group in TOMBOLA 2009. There were no cases of
invasive cancer in the two other included trials (Flannelly 1994;
Kitchener 2004).
Default rates
All five included trials reported on the non-compliance rates
for immediate colposcopy versus cytological surveillance (Table
1). Two reported non-attendance rates at six and 12 months
(Kitchener 2004; TOMBOLA 2009), two at 24 months (ALTS
2003; Shafi 1997) and one for all the time points (6, 12 and 24
months) (Flannelly 1994). The risk of non-compliance was signif-
icantly greater for the repeat cytology arm and increased with the
length of the follow-up. TOMBOLA 2009, the largest study and
one with high methodological quality, reported an almost double
risk of default for women followed up in the community when
compared to those referred to immediate colposcopy (6 months:
RR 1.88, 95% CI 1.56 to 2.27; 12 months: RR 2.16, 95% CI
1.80 to 2.59) (Table 1). The magnitude of effect was much greater
in the remaining trials. In ALTS 2003 the RR for cumulative risk
of default at 24 months was up to 27.42 (95% CI 10.17 to 73.93)
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for the surveillance arm at the exit exam, as opposed to the im-
mediate colposcopy group (Table 1). The study setting and pro-
tocols varied greatly between the included trials, which could well
explain the observed differences in default rates between studies.
The meta-analysis suggested that the risk for non-compliance was
higher for the repeat cytology group with a four-fold increase at
6 months, a six-fold increase at 12 months and a 19-fold increase
at 24 months (6 months: RR 3.85, 95% CI 1.27 to 11.63; 12
months: RR 6.60, 95% CI 1.49 to 29.29; 24 months: RR 19.1
95% CI 9.02 to 40.43). The inter-study heterogeneity was con-
siderable for the analysis at six and 12 months (P = 0.02, I2 = 76%
and P < 0.0004, I2 = 87%, respectively), and we therefore regarded
this as moderate-quality evidence, whereas we considered the evi-
dence to be of high quality at 24 months (Analysis 6.1; Figure 6;
Summary of findings for the main comparison).
Figure 6. Forest plot of comparison: default rates at different lengths of follow-up
Presence of after-effects
TOMBOLA 2009 was the only study that reported on the in-
cidence of after-effects based on a questionnaire completed six
weeks after immediate colposcopy or the first cytological follow-
up smear. Pain, bleeding, or vaginal discharge were all more com-
mon after immediate colposcopy than after cytology (Table 1).
Presence of anxiety, distress or depression
BothTOMBOLA2009 andKitchener 2004 reported incidence of
psychosocial morbidity in the randomisation groups (Table 1). In
TOMBOLA 2009, the authors reported the incidence of anxiety
and depression at six weeks, and thereafter at six-month intervals
until 30 months of surveillance. Anxiety, measured as score of 11
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or more on theHospital Anxiety and Depression anxiety sub scale,
was less common in the immediate colposcopy group compared to
the cytological surveillance group at six weeks (RR 0.58, 95% CI
0.43 to 0.79). There was no difference between the randomisation
groups thereafter. Incidence of depression, defined as a score of 8
or more on the Hospital Anxiety and Depression Scale (HADS) (
Zigmond 1983), did not differ between the twogroups throughout
the follow-up period. Kitchener 2004 used the General Health
Questionnaire (GHQ)-caseness (Bridges 1986) (defined as a score
of 4 or above) to measure the presence of anxiety or distress. There
were no differences between choice and no-choice arms at baseline
or after six and 12 months of surveillance. Given the differences
in the comparison groups and the assessment methods, a meta-
analysis was not possible.
Subgroup analyses
The optimum management option may be different for women
found to have ASCUS (borderline) or LSIL cytology (mild
dyskaryosis) in the baseline smear. We were unable to perform a
subgroup analysis for women with ASCUS cytology as only one
study (ALTS 2003) presented this separately. We could extract
separate data for women referred with LSIL cytology only from
two studies (ALTS 2003; Flannelly 1994). These studies reported
on the incidence of CIN2, CIN2+ and CIN3+ or worse at 24
months.
The incidence of the above histological outcomes was higher for
immediate colposcopy as opposed to cytology, although based on
small sample size (CIN2: 8.4% versus 11.6%, RR 1.72, 95%
CI 0.66 to 4.48; CIN2+: 23.4% versus 27.5%, RR 1.43, 95%
CI 0.51 to 4.01: CIN3+: 15% versus 15.9%, RR 1.24, 95% CI
0.39 to 3.94); all analyses demonstrated inter-study heterogeneity
(P < 0.01, I2 > 75%) and presented moderate-quality evidence
(Analysis 7.1).
ALTS 2003 revealed opposing direction of effect to the other in-
cluded studies in some of the outcomes assessed. We performed
a subgroup analysis that excluded this trial after 24 months of
surveillance and found little or no difference in the rate of CIN2
and CIN2+ between the immediate colposcopy and cytological
surveillance groups: CIN2 (RR 1.54, 95% CI 0.41 to 5.78, P =
0.02, I2= 83%) and for CIN2+ (RR 1.72, 95% CI 0.86 to 3.47,
P = 0.004, I2 = 88%; moderate-quality evidence). Immediate col-
poscopy increased the detection of CIN3+ as opposed to cytolog-
ical surveillance (30.9% versus 17%, RR 1.80, 95% CI 1.11 to
2.92, heterogeneity: P = 0.10, I2= 62%; high-quality evidence)
(Analysis 8.1; Analysis 8.2; Analysis 8.3).
D I S C U S S I O N
Summary of main results
The results of this meta-analysis suggest that the difference in the
CIN2 or CIN2+ rate detection was higher for the immediate col-
poscopy group at 18 months (without the exit examination), but
this was no longer the case at 24 months. Although this suggests
that colposcopy may allow earlier diagnosis of CIN2 lesions that
cytology would require longer to detect, it may also be explained
by the trials’ design. All participants in the cytological surveillance
arms underwent exit examination, a colposcopy with or without
treatment, irrespective of their cytological status in all trials. This
‘artificial’ detection of cases of high-grade disease at completion
would plausibly be lower in a ‘real-life’ setting in the cytological
surveillance arm; this may over inflate the reliability of repeat cy-
tology to detect high-grade disease.
Although the evidence suggests that theremay be little or no differ-
ence in the rate of CIN3+ detection at 24months between the two
arms, this result was mainly driven by a large RCT (ALTS 2003)
with almost opposing results to the remaining RCTs (Flannelly
1994; Kitchener 2004; Shafi 1997; TOMBOLA2009). The ALTS
study had a different design in that all women randomised and
analysed in the cytological surveillance arm had a repeat smear that
was assessed by an expert cytopathologist at recruitment. Almost
40% of CIN3+ lesions in the cytology arm were detected during
this repeat cytology smear and this may have inflated the ability
of cytology to detect disease when compared to immediate col-
poscopy (ALTS 2003). After exclusion of this trial, the difference
of CIN3+ detection favoured immediate colposcopy.
Women attending for immediate colposcopy after a single LSIL or
ASCUS smear were 50% more likely to have clinically insignifi-
cant HPV infections detected. The rates of histologically detected
lesions associated with HPV infection were lower for the repeat
cytology group, possibly explained by spontaneous regression of
clinically insignificant lesions during cytological surveillance. Sim-
ilarly, there was an increase in the detection of CIN1 lesions, sup-
porting the perception that immediate colposcopy may increase
the risk of over-intervention and over-treatment, by detection of
insignificant lesions that would otherwise spontaneously revert to
normal over time.
The evidence suggests that the risk for default to follow-up was
probably higher for the repeat cytology group at 6, 12 and 24
months. The difference between the two groups changed from
four-fold at 6 months and six-fold at 12 months up to 19-fold at
24 months. The point estimate at 24 months could well be bi-
ased and over-inflated due to selection of studies at that follow-up
window, that is, lack of data from one study (TOMBOLA 2009)
and inclusion of another with a very different trial setting (ALTS
2003). Compliance with follow-up still appeared to decline with
time and women may be at increased risk of invasion due to un-
derlying occult high-grade disease. The inter-study heterogeneity
was significant, possibly due to differences in the magnitude of the
default rates in the immediate colposcopy group between different
trials. These differences may be explained by differences in the de-
sign and randomisation process that could increase (TOMBOLA
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2009: randomisation and admittance to either colposcopy or cy-
tological surveillance after HPV test results) or decrease (ALTS
2003: immediate colposcopy preferably on the same day) the risk
of non-compliance in the immediate colposcopy arm. Only one
study reported on the after-effects - pain, bleeding or vaginal dis-
charge - and found that these were significantly more common
after immediate colposcopy (TOMBOLA 2009).Meta-analysis of
the after-effects and anxiety and depression was not possible.
Overall completeness and applicability of
evidence
This is the first meta-analysis that comprehensively investigates
the value of immediate colposcopy versus cytological surveillance
in women with lesions of equivocal significance in the absence of
HPV test. A previous systematic review only included three small
RCTs (Kyrgiou 2007a). Two large trials, one from the US (ALTS
2003) and the other from the UK (TOMBOLA 2009) addressed
this comparison comprehensively with large sample sizes. Because
all included studies were conducted in high-income setting, the
applicability of the evidence to lower income settings is not clear.
This systematic review still provides a comprehensive review of
the existing literature and meta-analytical pooling that will allow
clinicians to evaluate the trade-off between the risk of detection of
insignificant lesions versus the risk of poor compliance and non-
detection of occult high-grade disease.
Quality of the evidence
All of the included studies were RCTs, however, our analysis has
several limitations and the results should be interpreted with cau-
tion. There are only a small number of included studies, two
of which included a comparatively large number of participants
(ALTS 2003; TOMBOLA 2009), which may account for some
of the heterogeneity that was observed and which was consider-
able or substantial in many of the comparisons. It was this high
heterogeneity, as well as the presence of bias from study design
possibly resulting in falsely high CIN detection rate in the cyto-
logical surveillance arm in the 24-month follow-up window, that
accounted for the down-grading of the evidence to ’moderate’ or
’low’ in several cases following the GRADE assessment. Several of
the included studies varied in their design and comparison groups,
with the presence of exit examination and the length of follow-
up. Kitchener 2004, for example, had a choice and non-choice
arm, ALTS 2003 performed a repeat cytology at recruitment in
the cytology surveillance arm, while one of the older studies (Shafi
1997) performed a treatment for all participants at completion.
For many of the explored outcomes and comparisons, there was
substantial heterogeneity, possibly explained by the difference in
the studies’ design.
The results presented in the individual trials are those derived from
women who completed the given period of surveillance as the
presence or absence of disease cannot be verified in those women
who defaulted from surveillance. Furthermore, all the included
studies, apart from Kitchener 2004, performed exit examinations
at the time of the study completion for both arms, some of which
included an excision of the transformation zone for all subjects
(Shafi 1997). The comparison of the rates of different grades of
disease at the time of the study completion may represent an ‘ar-
tificial’ detection of lesions that would not have been detected in
the cytology arm in a ‘real-life’ setting, with the risk to inflate the
ability of repeat cytology to detect disease. We therefore consid-
ered the quality of evidence in the 24-month follow-up window
to be low.
Most of the included studies did not assess the impact of age
of the population in the preferred management approach. Only
TOMBOLA 2009 assessed the effect of age on histological out-
comes and concluded that the difference in cumulative incidence
of CIN2+ between the trial arms was more pronounced amongst
younger women (20 to 39 years), as opposed to older women (40
to 59 years). Furthermore, in younger women (age 20 to 39 years)
the risk ratios for CIN2 or worse weremarkedly higher thanCIN3
or worse.
Potential biases in the review process
All of the included studies were RCTs. It was not possible to blind
participants and personnel given the nature of the intervention.
The random sequence generation was considered appropriate in
all studies and the allocation concealment in all but one study
(Flannelly 1994), where the allocation concealment process was
not described in full. Only one study (TOMBOLA 2009) de-
scribed blinding of assessors; the colposcopist was blinded at exit
examination only with regards to the women’s cytology status, ran-
domisation category and any clinical outcomes. The lack of asses-
sor blinding in the other included studies (ALTS 2003; Flannelly
1994; Kitchener 2004; Shafi 1997) may have introduced a degree
of detection bias. Loss to follow-up rates were high overall ranging
from 14% to 42%, which may have introduced a degree of attri-
tion bias. The risk of selective reporting was considered low in all
trials.
In order to minimise bias whilst undertaking the review, two re-
view authors (MK and IK) independently reviewed the retrieved
citations and the extracted data. There was no discrepancy in the
included studies; some minor discrepancies in the data extraction
were resolved with discussion and the involvement of a third re-
viewer (MA) if necessary.
Agreements and disagreements with other
studies or reviews
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Almost one in ten women screened in the UK will have a minor
lesion detected in her smear. Several authorities recommend con-
servative surveillance in the primary care setting, as spontaneous
regression of most of these lesions will occur (Kyrgiou 2007a).
Referral to colposcopy may increase psychological morbidity for
these women who experience similar levels of anxiety to those re-
ferred with high-grade disease (TOMBOLA 2009). This increase
in anxiety appears to be transient and is no different after six weeks.
Furthermore, further investigation of lesions that were deemed to
regress without intervention increases the risk of over-intervention
and over-treatment with subsequent possible adverse reproduc-
tive sequale (Arbyn 2008; Founta 2010; Kyrgiou 2006;Kyrgiou
2012a; Kyrgiou 2014;Kyrgiou 2015; Kyrgiou 2016a). The oppo-
nents supporting immediate assessment with colposcopy empha-
sise that protracted attendance for repeat cytology decreases with
time (Soutter 2012) and this was also confirmed in this analysis.
The evidence suggests that approximately one third of women re-
ferred with borderline or low-grade cytological abnormalities have
anoccult high-grade disease andnon-compliancewith surveillance
may put some women at risk of developing invasive disease (Bolger
1988; Contreras-Melendez 1992; Giles 1989; Paraskevaidis 2002;
Soutter 1986; Walker 1986). The participants lost to follow-up
due to poor compliance in these trials could result in an underesti-
mation of the true number of high-grade lesions that were missed
in the cytology group.
The financial implications of the two approaches to health ser-
vices should also be considered. Cost-effectiveness analysis in some
of the earlier studies suggested that referral to colposcopy is a
more cost-effective alternative to repeat cytology (Flannelly 1997;
Johnson 1993). The cost-effectiveness analysis of the TOMBOLA
trial suggested no difference amongst the two approaches although
cytological surveillance was less costly (TOMBOLA 2009). The
ALTS trial suggested that HPV-triage or repeat cytology of a sin-
gle repeat smear was cost-effective, although there was no differ-
ence in cost-effectiveness if two or more smears were performed
(ALTS 2003). The cost-effectiveness of the two approaches largely
depends on the policy of subsequent surveillance in the case of
negative colposcopy; this was not addressed in any of the included
studies.
Strong evidence supports the preferential use of HPV test partic-
ularly in the triage of women with ASCUS (borderline) cytology
(Arbyn 2004; Arbyn 2012; Arbyn 2013a) that would benefit from
colposcopy as amore accurate and cost-effectivemodality. Its value
is less pronounced in younger women below the age of 30 and
women with LSIL (mild dyskaryosis) (Arbyn 2009; Arbyn 2013a).
However, this test is not always readily available, particularly in
low-resource settings. In Europe alone, one in ten women with
ASCUS cytology and four in ten women with LSIL will not have a
triageHPV test and clear recommendations are required tomanage
such cases. Newermarkers such as mRNA or p16/Ki67 immunos-
taining have more recently shown promising results claiming an
equal sensitivity to that of the DNA test but with improved speci-
ficity in this setting (Arbyn 2013b; Nasioutziki 2011; Tsoumpou
2009; Tsoumpou 2011). Further combinations of novel biomark-
ers and Clinical Decision Support Scoring Systems (DSSS) based
onmathematical modelling that will create user-friendly tools have
the potential to further improve the management of this popula-
tion (Bountris 2014; Karakitsos 2011; Karakitsos 2012; Kyrgiou
2016b).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In the absence of HPV testing, women could be referred for im-
mediate colposcopy after a single low-grade or borderline cervi-
cal smear, if compliance with cytological surveillance is expected
to be poor. When follow-up compliance is expected to be good,
repeated cytology may be preferred. This latter approach may re-
duce the risk of over-diagnosis and over-treatment (diagnosis and
treatment of clinically insignificant lesions). Clinicians should be
cautious and intervene only in women that are found to have high-
grade disease at colposcopy, in order to minimise the risk of over-
treatment. There is a clear need for a reflex triage method that
can make distinction between women needing diagnostic work-
up and those who can be released safely to routine screening.
Implications for research
Immediate colposcopy may not increase the detection of high-
grade disease, compared to continued cytological surveillance over
two years. Compliance, however, declines over time and is prob-
ably increased for women under cytological surveillance. In the
absence of HPV test, a general policy could be immediate col-
poscopy after a single low-grade or borderline cervical smear when
poor compliance is anticipated.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ALTS 2003
Methods 3-arm RCT
Participants 5060 women (3488 women, ASCUS smear and 1572 women, LSIL smear)
Study arms:
1. Immediate colposcopy (N = 1836; LSIL = 673, ASCUS = 1163)
2. HPV triage (N = 1385; LSIL = 224, ASCUS = 1161)
3. Cytological follow-up (N = 1839; LSIL = 675, ASCUS = 1164)
Inclusion criteria:
• Cytologic diagnosis of LSIL or ASCUS
• Aged 18 or older
• Able to provide informed consent and likely to participate the full duration of trial
Exclusion criteria:
• Prior hysterectomy or treatment of cervix
• Pregnant at the time
Interventions All
• Enrollment pelvic examination with collection of HPV-sample and liquid-based
cytology
• Exit colposcopy at 24 months. Treatment if CIN2 or 3 in biopsy and CIN1 with
previous LSIL/ASCUS and HPV+
Colposcopy indications:
1. Immediate colposcopy at the date of recruitment or within 3 weeks. Treatment if
CIN2 or 3 in biopsy
2. Referral to colposcopy if the HPV test positive or missing or if enrolment cytology
HSIL. Treatment if CIN2 or 3 in biopsy
3. Referral to colposcopy if cytology HSIL. Treatment if CIN2 or 3 in biopsy
LSIL only
• Due to safety analysis results later all women with initial LSIL smear referred to
colposcopy during the trial
• At each follow-up visit every six months a pelvic examination, cervicography,
cervical smear and HPV-test were done.
Outcomes • Default rates
• Cumulative CIN2+ & CIN3+ incidence and results at recruitment, during
surveillance and at 24 months’ exit examination
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Telephone-based central randomisation service used. Sequence
generation not described in detail, but not estimated to induce
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ALTS 2003 (Continued)
bias
Allocation concealment (selection bias) Low risk Allocation done from central point
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants was not possible and personnel were
not blinded of allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of investigators undertaking follow-up assessments was
not described in detail
“all available clinical information was unmasked and provided
to the clinician conducting the exit pelvic examination and col-
poscopy.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up were disclosed (ASCUS: 14.2% at 24
months in the surveillance group, LSIL: 16.3% at 24 months
in the surveillance group) and the analyses were conducted as
specified a priori. Loss to follow-up might have introduced only
small bias to histology results
Selective reporting (reporting bias) Low risk Pre-published trial protocol available, outcome reporting done
according to protocol
Other bias High risk Source of funding reported; competing interests reported. Eth-
ical approval & informed consent from participants obtained.
Repeat smear at randomisation visit and exit colposcopy at 24
months, both could potentially introduce detection bias and
over inflate the detection rate of pre-invasive lesions in the cy-
tological surveillance arm at 24 months
Flannelly 1994
Methods 4-arm RCT
Participants 902 women, presenting with mildly or moderately dyskaryotic smear for the first time
Study arms:
1. Immediate colposcopy +/- treatment (n = 227)
2. Surveillance for 6 months (n = 225)
3. Surveillance for 12 months (n = 223)
4. Surveillance for 24 months (n = 227)
Inclusion criteria:
• Mild or moderate dyskaryosis in first abnormal smear
Exclusion criteria:
• None given.
Interventions Group 1. Immediate colposcopy with biopsies +/- treatment (n = 227)
Group 2. 6-month surveillance (n = 225):
• Cytology and colposcopy with histological diagnosis (biopsy and/or LLETZ) at 6
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Flannelly 1994 (Continued)
months
Group 3. 12-month surveillance (n = 223):
• Surveillance at 6-month intervals through cytology and colposcopy with
histological diagnosis (biopsy and/or LLETZ) at the end of surveillance period
• Immediate LLETZ if severe dyskaryosis in smear or suspicion of microinvasion at
colposcopy.
Group 4. 24-month surveillance (n = 227):
• Surveillance at 6-month intervals through cytology and colposcopy with
histological diagnosis (biopsy and/or LLETZ) at the end of surveillance period
• Immediate LLETZ if severe dyskaryosis in smear or suspicion of microinvasion at
colposcopy
Outcomes • Default rates
◦ Defined as those who did not complete the protocol in question
• Histology at the end of each surveillance period
◦ From punch biopsy or LLETZ specimen, whichever showed worse lesion
• Final smear test result
• CIN3 prevalence in relation to number of non-dyskaryotic smears
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...all eligible women randomised by serial allocation to one of
four groups.”
Allocation concealment (selection bias) Unclear risk Method of concealment not described in sufficient detail
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants was not possible and blinding of per-
sonnel was not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessment not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 109/675 women in the surveillance arms defaulted from study,
rates being higher with longer follow-up (9.8% at 6months, 15.
2% at 12 months, and 23.3% at 24 months). More specific rea-
sons not available. Significant default rates might bias histology
results
Selective reporting (reporting bias) Low risk Protocol not available. Results still reported comprehensively
and reporting considered not to introduce bias
30Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
(Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Flannelly 1994 (Continued)
Other bias High risk Conflict of interest not reported; source of funding not reported;
details of ethical approval not stated. Missing information still
considered not to introduce bias
All women in the surveillance arm had colposcopy in addition
to smear, which could introduce bias and over inflate the de-
tection rates in the surveillance arm at 6, 12 and 24 months of
surveillance
Kitchener 2004
Methods 2-arm RCT with Zelen randomisation
Participants 712 women pre-randomised, with mild dyskaryosis for the first time or recurrent bor-
derline change on routine cervical screening in primary care
Aged 20 to 60, not pregnant, no abnormal vaginal bleeding
Of 712 pre-randomised women, 476 decided to participate in the study
Study arms:
1. No choice arm (n = 243): surveillance for 12 months
2. Choice arm (n = 233)
Inclusion criteria:
• Recurrent borderline or first mild dyskaryotic smear
• Aged 20 to 60
Exclusion criteria:
• Pregnancy
• Abnormal vaginal bleeding
Interventions Group 1. No-choice arm (n = 243)
• Cytological surveillance at 6 months & 12 months, with colposcopy +/-
treatment (LLETZ) if either follow-up smear abnormal
• General health questionnaire at baseline, 6 months, and 12 months
Group 2. Choice arm (n = 233)
Women were given the opportunity to choose between a) and b):
• choice a) immediate colposcopy (n = 130)
◦ immediate colposcopy with biopsies +/- treatment (LLETZ)
◦ General Health Questionnaire at baseline, at immediate colposcopy, 6
months, and 12 months
• choice b) cytological surveillance (n = 103)
◦ Cytological surveillance at 6 months and 12 months, with colposcopy +/-
treatment (LLETZ) if either follow-up smear abnormal
◦ General Health Questionnaire at baseline, 6 months, and 12 months
Outcomes • Default rates
◦ reported at 6 months and at 12 months
◦ defined as women lost to follow-up at respective time points
• Cumulative histology at the end of 12-month surveillance period
◦ Based on biopsy or LLETZ-specimen
• Psychological morbidity and anxiety levels (General Health Questionnaire scores)
◦ GHQ-caseness, defined as 4 or more points from the questionnaire
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Kitchener 2004 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation into two study arms prior
to consent using computer-generated random
numbers
Allocation concealment (selection bias) Low risk Central allocation used. In one of the study
arms the participants themselves chose the in-
tervention group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and investigators were not
blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessment was not blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk 712 pre-randomised, 476 participated. Rea-
sons for non-participation reported, no clear
differences between randomisation groups
172/476 were lost to follow-up, no specific
reasons stated. Adequate sample sizemight not
have been achieved for all outcomes
Selective reporting (reporting bias) Low risk Pre-trial protocol was not available. Results
still reported comprehensively
Other bias High risk Project funding reported; conflicts of inter-
est not stated. Local ethical approval and in-
formed consent from participants obtained.
Missing information still considered not to
introduce bias. Used Zelen randomisation,
where some participants were able to choose
whether to have immediate colposcopy or cy-
tological surveillance, which might well bias
the results included here
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Shafi 1997
Methods 2-arm RCT
Participants 353 women with borderline or mild dyskaryotic smear
Study arms:
1. Immediate treatment (n = 182)
2. Surveillance for 24 months (n = 171)
Inclusion criteria:
• Borderline or mild dyskaryotic smear
• Age < 35
• Fully visible TZ and no features of invasion at colposcopy
Exclusion criteria:
• Previous smear more abnormal than mild dyskaryosis
• Previous CIN
• Normal colposcopy at baseline
Interventions Group 1. Immediate treatment (n = 182)
• - Immediate treatment (LLETZ)
Group 2. Deferred treatment (n = 171)
• Cytological and colposcopic surveillance at 6 month intervals, treatment
(LLETZ) at 24 months
• Treatment during surveillance if follow-up cytology severe dyskaryosis or worse
Outcomes • Default rates
◦ defined as those who did not complete the protocol
• 2. Histology
◦ From LLETZ specimen at the immediate treatment
◦ From LLETZ specimen at the end of 24m surveillance period
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using a sequence of random numbers generated by
computer
Allocation concealment (selection bias) Low risk Total allocation concealment as randomisation performed indi-
vidually from a central point
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding participants was not possible and personnel were not
blinded to allocation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Investigators undertaking follow-up were not blinded.
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Shafi 1997 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 36/171 lost to follow-up in deferred treatment group, 1/181 in
the immediate colposcopy group. More specific reasons not re-
ported. The 20% lost to follow-up in other armmight introduce
bias to histology results
Selective reporting (reporting bias) Low risk Pre-trial protocol was not available. Results still reported com-
prehensively
Other bias High risk Individual sources of funding reported, conflicts of interests not
declared. Local ethical approval and informed consent from par-
ticipants obtained. Missing information still considered not to
introduce bias. All women in the surveillance arm had deferred
treatment at 24 months regardless of cytology, which could in-
troduce bias and over inflate the CIN detection rate in the
surveillance-arm at 24 months
TOMBOLA 2009
Methods 2-arm RCT
Participants 4439 women, aged 20-59, with cytological result showing:
Study arms:
1. Cytological surveillance every 6 months up to 3 years (n = 2223)
2. Immediate referral to colposcopy and surveillance according to general guidelines
(n = 2216)
Inclusion criteria:
• Borderline nuclear abnormality and borderline or mild dyskaryosis in repeat
smear after 6 months (first phase of trial).
• Single borderline nuclear abnormality (second phase)
• Aged 20-59
Exclusion criteria
• Pregnancy at the time of recruitment
• Previous cervical treatment
Interventions Group 1. Surveillance arm (n = 2223)
• HPV-test at recruitment
• Cytological surveillance every 6 months
• Questionnaire regarding anxiety, depression and colposcopy after-effects every 6
months
• Exit examination at 3 years: colposcopy, and LLETZ if TZ abnormal
Group 2. Immediate colposcopy arm (n = 2216), second randomisation at colposcopy
to a) or b)
a) Biopsy and selective recall for LLETZ based on histology on biopsy
• HPV-test at recruitment
• Questionnaire regarding anxiety, depression and colposcopy after-effects every 6
months.
• Follow-up with cytology and / or colposcopy based on local guidelines
• Exit examination at 3 years: colposcopy, and LLETZ if TZ abnormal.
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TOMBOLA 2009 (Continued)
b) Immediate treatment (LLETZ)
• - HPV-test at recruitment-
• Questionnaire regarding anxiety, depression and colposcopy after-effects every 6
months.-Follow-up with cytology and / or colposcopy based on local guidelines- Exit
examination at 3 years: colposcopy, and LLETZ if TZ abnormal.
Outcomes • Cumulative incidence of CIN grade 2 or more severe disease
◦ Based on biopsy or LLETZ-specimen
• Cumulative incidence of CIN grade 3 or worse
◦ Based on biopsy or LLETZ-specimen
• Anxiety and depression
◦ based on 6-monthly questionnaire
• Other self reported after-effects
◦ based on 6-monthly questionnaire
• Rates of non-attendance
◦ Defined as non-attendance at given follow-up visit, or attended more than 6
months after the appointment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Touch-telephone stratified randomisation used
Allocation concealment (selection bias) Low risk Allocation done from central point
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants not possible to blind. Blinding of personnel not
described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk At exit examination the colposcopist was blinded to the women’s
initial cytology status, her randomisation and any clinical out-
comes
Blinding of colposcopists or pathologists at other stages was not
reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Before the first examination 107/2223 in the surveillance arm,
155/2216 in the colposcopy arm were lost to follow-up. 1296
(58.3%) women in the surveillance arm and 1389 (62.7%) in
the colposcopy arm attended the exit examination. Power cal-
culations were based on 4500 participants. The significant loss
to follow-up and differences between arms might introduce bias
to histology results
Selective reporting (reporting bias) Low risk Pre-published trial protocol available, outcome reporting ac-
cording to protocol
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TOMBOLA 2009 (Continued)
Other bias High risk Source of funding reported; Competing interests reported. Eth-
ical approval & informed consent from participants obtained.
All women were invited to an exit examination at 36 months,
where colposcopy was performed regardless of smear results.
This could introduce bias and over inflate the CIN detection
rates in surveillance arm at 36 months
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
De Bie 2011 Not RCT (retrospective cohort study)
Elit 2011 Exposure not of interest (natural history of CIN 1)
36Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
(Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Occurence of CIN2+ at different lengths of follow-up: immediate colposcopy versus cytological
surveillance
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Occurrence of CIN2+ 3 Risk Ratio (IV, Random, 95% CI) Subtotals only
1.1 18 months’ surveillance 2 4028 Risk Ratio (IV, Random, 95% CI) 1.50 [1.12, 2.01]
1.2 24 months’ surveillance 3 4331 Risk Ratio (IV, Random, 95% CI) 1.14 [0.66, 1.97]
Comparison 2. Occurence of CIN3+ at different lengths of follow-up: immediate colposcopy versus cytological
surveillance
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Occurrence of CIN3+ 4 Risk Ratio (IV, Random, 95% CI) Subtotals only
1.1 12 months’ surveillance 2 676 Risk Ratio (IV, Random, 95% CI) 2.07 [1.54, 2.79]
1.2 18 months’ surveillance 2 4028 Risk Ratio (IV, Random, 95% CI) 1.24 [0.77, 1.98]
1.3 24 months’ surveillance 3 4331 Risk Ratio (IV, Random, 95% CI) 1.02 [0.53, 1.97]
Comparison 3. Histology at 12 months: immediate colposcopy versus cytological surveillance
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Presence of any CIN in histology
at 12 months
2 676 Risk Ratio (IV, Random, 95% CI) 1.72 [1.09, 2.70]
2 Presence of CIN1/2 in histology
at 12 months
2 676 Risk Ratio (IV, Random, 95% CI) 1.69 [0.83, 3.43]
3 Presence of CIN3+ in histology
at 12 months
2 676 Risk Ratio (IV, Random, 95% CI) 1.63 [1.25, 2.12]
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Comparison 4. Histology at 24 months: immediate colposcopy versus cytological surveillance
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Histology at 24 months 3 Risk Ratio (IV, Random, 95% CI) Subtotals only
1.1 HPV/Koilocytic atypia 2 656 Risk Ratio (IV, Random, 95% CI) 1.49 [1.17, 1.90]
1.2 Any CIN 2 656 Risk Ratio (IV, Random, 95% CI) 2.02 [1.33, 3.08]
1.3 CIN1 2 656 Risk Ratio (IV, Random, 95% CI) 2.58 [1.69, 3.94]
1.4 CIN2 3 4331 Risk Ratio (IV, Random, 95% CI) 1.25 [0.80, 1.96]
1.5 CIN2+ 3 4331 Risk Ratio (IV, Random, 95% CI) 1.14 [0.66, 1.97]
1.6 CIN3+ 3 4331 Risk Ratio (IV, Random, 95% CI) 1.02 [0.53, 1.97]
Comparison 5. Occurence of CIN2 at different lengths of follow-up: Immediate colposcopy versus cytological
surveillance
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Occurrence of CIN2 3 Risk Ratio (IV, Random, 95% CI) Subtotals only
1.1 18 months’ surveillance 2 4028 Risk Ratio (IV, Random, 95% CI) 2.04 [1.52, 2.73]
1.2 24 months’ surveillance 3 4331 Risk Ratio (IV, Random, 95% CI) 1.45 [0.87, 2.40]
Comparison 6. Default rates: immediate colposcopy versus cytological surveillance
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Default rates 5 Risk Ratio (IV, Random, 95% CI) Subtotals only
1.1 Default rates at 6 months 3 5117 Risk Ratio (IV, Random, 95% CI) 3.85 [1.27, 11.63]
1.2 Default rates at 12 months 3 5115 Risk Ratio (IV, Random, 95% CI) 6.60 [1.49, 29.29]
1.3 Default rates at 24 months 3 4331 Risk Ratio (IV, Random, 95% CI) 19.10 [9.02, 40.43]
38Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
(Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 7. Histology at 24 months: immediate colposcopy versus cytological surveillance, LSIL/mild
dyskaryosis only
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 CIN incidence at 24 months,
after LSIL/mild dyskaryosis at
baseline
2 Risk Ratio (IV, Random, 95% CI) Subtotals only
1.1 CIN2 incidence at 24
months
2 1651 Risk Ratio (IV, Random, 95% CI) 1.72 [0.66, 4.48]
1.2 CIN2+ incidence at 24
months
2 1651 Risk Ratio (IV, Random, 95% CI) 1.43 [0.51, 4.01]
1.3 CIN3+ incidence at 24
months
2 1651 Risk Ratio (IV, Random, 95% CI) 1.24 [0.39, 3.94]
Comparison 8. Histology at 24 months: immediate colposcopy versus cytological surveillance, excluding 1 trial
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Presence of CIN2 in histology at
24 months
2 656 Risk Ratio (IV, Random, 95% CI) 1.54 [0.41, 5.78]
2 Presence of CIN2+ in histology
at 24 months
2 656 Risk Ratio (IV, Random, 95% CI) 1.72 [0.86, 3.47]
3 Presence of CIN3+ in histology
at 24 months
2 656 Risk Ratio (IV, Random, 95% CI) 1.80 [1.11, 2.92]
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Analysis 1.1. Comparison 1 Occurence of CIN2+ at different lengths of follow-up: immediate colposcopy
versus cytological surveillance, Outcome 1 Occurrence of CIN2+.
Review: Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
Comparison: 1 Occurence of CIN2+ at different lengths of follow-up: immediate colposcopy versus cytological surveillance
Outcome: 1 Occurrence of CIN2+
Study or subgroup
Immediate
col-
poscopy
Cytological
surveillance Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 18 months’ surveillance
Shafi 1997 43/182 16/171 19.8 % 2.53 [ 1.48, 4.31 ]
ALTS 2003 127/673 95/675 40.9 % 1.34 [ 1.05, 1.71 ]
ALTS 2003 119/1163 92/1164 39.4 % 1.29 [ 1.00, 1.68 ]
Subtotal (95% CI) 2018 2010 100.0 % 1.50 [ 1.12, 2.01 ]
Total events: 289 (Immediate colposcopy), 203 (Cytological surveillance)
Heterogeneity: Tau2 = 0.04; Chi2 = 5.14, df = 2 (P = 0.08); I2 =61%
Test for overall effect: Z = 2.69 (P = 0.0071)
2 24 months’ surveillance
Flannelly 1994 98/145 44/158 25.1 % 2.43 [ 1.84, 3.20 ]
Shafi 1997 43/182 34/171 23.5 % 1.19 [ 0.80, 1.77 ]
ALTS 2003 127/673 151/675 25.8 % 0.84 [ 0.68, 1.04 ]
ALTS 2003 119/1163 168/1164 25.7 % 0.71 [ 0.57, 0.88 ]
Subtotal (95% CI) 2163 2168 100.0 % 1.14 [ 0.66, 1.97 ]
Total events: 387 (Immediate colposcopy), 397 (Cytological surveillance)
Heterogeneity: Tau2 = 0.29; Chi2 = 52.27, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 0.47 (P = 0.64)
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Analysis 2.1. Comparison 2 Occurence of CIN3+ at different lengths of follow-up: immediate colposcopy
versus cytological surveillance, Outcome 1 Occurrence of CIN3+.
Review: Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
Comparison: 2 Occurence of CIN3+ at different lengths of follow-up: immediate colposcopy versus cytological surveillance
Outcome: 1 Occurrence of CIN3+
Study or subgroup
Immediate
col-
poscopy
Cytological
surveillance Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 12 months’ surveillance
Flannelly 1994 66/145 32/158 69.4 % 2.25 [ 1.57, 3.21 ]
Kitchener 2004 22/130 24/243 30.6 % 1.71 [ 1.00, 2.93 ]
Subtotal (95% CI) 275 401 100.0 % 2.07 [ 1.54, 2.79 ]
Total events: 88 (Immediate colposcopy), 56 (Cytological surveillance)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 4.79 (P < 0.00001)
2 18 months’ surveillance
Shafi 1997 35/182 14/171 26.8 % 2.35 [ 1.31, 4.21 ]
ALTS 2003 64/673 59/675 36.7 % 1.09 [ 0.78, 1.52 ]
ALTS 2003 58/1163 66/1164 36.5 % 0.88 [ 0.62, 1.24 ]
Subtotal (95% CI) 2018 2010 100.0 % 1.24 [ 0.77, 1.98 ]
Total events: 157 (Immediate colposcopy), 139 (Cytological surveillance)
Heterogeneity: Tau2 = 0.13; Chi2 = 8.12, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 0.88 (P = 0.38)
3 24 months’ surveillance
Flannelly 1994 66/145 32/158 25.1 % 2.25 [ 1.57, 3.21 ]
Shafi 1997 35/182 24/171 23.7 % 1.37 [ 0.85, 2.20 ]
ALTS 2003 58/1163 108/1164 25.6 % 0.54 [ 0.39, 0.73 ]
ALTS 2003 64/673 93/675 25.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 2163 2168 100.0 % 1.02 [ 0.53, 1.97 ]
Total events: 223 (Immediate colposcopy), 257 (Cytological surveillance)
Heterogeneity: Tau2 = 0.41; Chi2 = 41.92, df = 3 (P<0.00001); I2 =93%
Test for overall effect: Z = 0.07 (P = 0.94)
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Analysis 3.1. Comparison 3 Histology at 12 months: immediate colposcopy versus cytological surveillance,
Outcome 1 Presence of any CIN in histology at 12 months.
Review: Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
Comparison: 3 Histology at 12 months: immediate colposcopy versus cytological surveillance
Outcome: 1 Presence of any CIN in histology at 12 months
Study or subgroup
Immediate
col-
poscopy Surveillance Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Flannelly 1994 121/145 96/158 52.1 % 1.37 [ 1.19, 1.59 ]
Kitchener 2004 83/130 71/243 47.9 % 2.19 [ 1.73, 2.76 ]
Total (95% CI) 275 401 100.0 % 1.72 [ 1.09, 2.70 ]
Total events: 204 (Immediate colposcopy), 167 (Surveillance)
Heterogeneity: Tau2 = 0.10; Chi2 = 10.90, df = 1 (P = 0.00096); I2 =91%
Test for overall effect: Z = 2.33 (P = 0.020)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Histology at 12 months: immediate colposcopy versus cytological surveillance,
Outcome 2 Presence of CIN1/2 in histology at 12 months.
Review: Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
Comparison: 3 Histology at 12 months: immediate colposcopy versus cytological surveillance
Outcome: 2 Presence of CIN1/2 in histology at 12 months
Study or subgroup
Immediate
col-
poscopy Surveillance Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Flannelly 1994 55/145 51/158 50.1 % 1.18 [ 0.86, 1.60 ]
Kitchener 2004 61/130 47/243 49.9 % 2.43 [ 1.77, 3.32 ]
Total (95% CI) 275 401 100.0 % 1.69 [ 0.83, 3.43 ]
Total events: 116 (Immediate colposcopy), 98 (Surveillance)
Heterogeneity: Tau2 = 0.24; Chi2 = 10.42, df = 1 (P = 0.001); I2 =90%
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Histology at 12 months: immediate colposcopy versus cytological surveillance,
Outcome 3 Presence of CIN3+ in histology at 12 months.
Review: Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
Comparison: 3 Histology at 12 months: immediate colposcopy versus cytological surveillance
Outcome: 3 Presence of CIN3+ in histology at 12 months
Study or subgroup
Immediate
Col-
poscopy Surveillance Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Flannelly 1994 66/145 45/158 75.7 % 1.60 [ 1.18, 2.17 ]
Kitchener 2004 22/130 24/243 24.3 % 1.71 [ 1.00, 2.93 ]
Total (95% CI) 275 401 100.0 % 1.63 [ 1.25, 2.12 ]
Total events: 88 (Immediate Colposcopy), 69 (Surveillance)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 3.59 (P = 0.00033)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Histology at 24 months: immediate colposcopy versus cytological surveillance,
Outcome 1 Histology at 24 months.
Review: Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
Comparison: 4 Histology at 24 months: immediate colposcopy versus cytological surveillance
Outcome: 1 Histology at 24 months
Study or subgroup
Immediate
Col-
poscopy Surveillance Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 HPV/Koilocytic atypia
Flannelly 1994 13/145 11/158 9.9 % 1.29 [ 0.60, 2.78 ]
Shafi 1997 92/182 57/171 90.1 % 1.52 [ 1.17, 1.96 ]
Subtotal (95% CI) 327 329 100.0 % 1.49 [ 1.17, 1.90 ]
Total events: 105 (Immediate Colposcopy), 68 (Surveillance)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 3.23 (P = 0.0013)
2 Any CIN
Flannelly 1994 121/145 53/158 51.6 % 2.49 [ 1.97, 3.13 ]
Shafi 1997 88/182 51/171 48.4 % 1.62 [ 1.23, 2.13 ]
Subtotal (95% CI) 327 329 100.0 % 2.02 [ 1.33, 3.08 ]
Total events: 209 (Immediate Colposcopy), 104 (Surveillance)
Heterogeneity: Tau2 = 0.07; Chi2 = 5.47, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 3.29 (P = 0.0010)
3 CIN1
Flannelly 1994 23/145 9/158 33.0 % 2.78 [ 1.33, 5.82 ]
Shafi 1997 45/182 17/171 67.0 % 2.49 [ 1.48, 4.17 ]
Subtotal (95% CI) 327 329 100.0 % 2.58 [ 1.69, 3.94 ]
Total events: 68 (Immediate Colposcopy), 26 (Surveillance)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 4.39 (P = 0.000011)
4 CIN2
Flannelly 1994 32/145 12/158 22.0 % 2.91 [ 1.56, 5.42 ]
Shafi 1997 8/182 10/171 14.9 % 0.75 [ 0.30, 1.86 ]
ALTS 2003 63/673 58/675 31.6 % 1.09 [ 0.78, 1.53 ]
ALTS 2003 61/1163 60/1164 31.4 % 1.02 [ 0.72, 1.44 ]
Subtotal (95% CI) 2163 2168 100.0 % 1.25 [ 0.80, 1.96 ]
Total events: 164 (Immediate Colposcopy), 140 (Surveillance)
Heterogeneity: Tau2 = 0.13; Chi2 = 9.87, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 0.99 (P = 0.32)
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(. . . Continued)
Study or subgroup
Immediate
Col-
poscopy Surveillance Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
5 CIN2+
Flannelly 1994 98/145 44/158 25.1 % 2.43 [ 1.84, 3.20 ]
Shafi 1997 43/182 34/171 23.5 % 1.19 [ 0.80, 1.77 ]
ALTS 2003 127/673 151/675 25.8 % 0.84 [ 0.68, 1.04 ]
ALTS 2003 119/1163 168/1164 25.7 % 0.71 [ 0.57, 0.88 ]
Subtotal (95% CI) 2163 2168 100.0 % 1.14 [ 0.66, 1.97 ]
Total events: 387 (Immediate Colposcopy), 397 (Surveillance)
Heterogeneity: Tau2 = 0.29; Chi2 = 52.27, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 0.47 (P = 0.64)
6 CIN3+
Flannelly 1994 66/145 32/158 25.1 % 2.25 [ 1.57, 3.21 ]
Shafi 1997 35/182 24/171 23.7 % 1.37 [ 0.85, 2.20 ]
ALTS 2003 64/673 93/675 25.6 % 0.69 [ 0.51, 0.93 ]
ALTS 2003 58/1163 108/1164 25.6 % 0.54 [ 0.39, 0.73 ]
Subtotal (95% CI) 2163 2168 100.0 % 1.02 [ 0.53, 1.97 ]
Total events: 223 (Immediate Colposcopy), 257 (Surveillance)
Heterogeneity: Tau2 = 0.41; Chi2 = 41.92, df = 3 (P<0.00001); I2 =93%
Test for overall effect: Z = 0.07 (P = 0.94)
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Analysis 5.1. Comparison 5 Occurence of CIN2 at different lengths of follow-up: Immediate colposcopy
versus cytological surveillance, Outcome 1 Occurrence of CIN2.
Review: Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
Comparison: 5 Occurence of CIN2 at different lengths of follow-up: Immediate colposcopy versus cytological surveillance
Outcome: 1 Occurrence of CIN2
Study or subgroup
Immediate
col-
poscopy
Cytological
surveillance Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 18 months’ surveillance
Shafi 1997 8/182 2/171 3.6 % 3.76 [ 0.81, 17.45 ]
ALTS 2003 61/1163 26/1164 41.8 % 2.35 [ 1.49, 3.69 ]
ALTS 2003 63/673 36/675 54.6 % 1.76 [ 1.18, 2.61 ]
Subtotal (95% CI) 2018 2010 100.0 % 2.04 [ 1.52, 2.73 ]
Total events: 132 (Immediate colposcopy), 64 (Cytological surveillance)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.54, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 4.78 (P < 0.00001)
2 24 months’ surveillance
Flannelly 1994 32/145 12/158 23.2 % 2.91 [ 1.56, 5.42 ]
Shafi 1997 8/182 10/171 16.6 % 0.75 [ 0.30, 1.86 ]
ALTS 2003 63/673 36/675 29.4 % 1.76 [ 1.18, 2.61 ]
ALTS 2003 61/1163 60/1164 30.7 % 1.02 [ 0.72, 1.44 ]
Subtotal (95% CI) 2163 2168 100.0 % 1.45 [ 0.87, 2.40 ]
Total events: 164 (Immediate colposcopy), 118 (Cytological surveillance)
Heterogeneity: Tau2 = 0.18; Chi2 = 11.58, df = 3 (P = 0.01); I2 =74%
Test for overall effect: Z = 1.44 (P = 0.15)
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Analysis 6.1. Comparison 6 Default rates: immediate colposcopy versus cytological surveillance, Outcome
1 Default rates.
Review: Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
Comparison: 6 Default rates: immediate colposcopy versus cytological surveillance
Outcome: 1 Default rates
Study or subgroup Surveillance
Immediate
colposcopy Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Default rates at 6 months
Flannelly 1994 19/160 0/145 11.9 % 35.37 [ 2.15, 580.52 ]
Kitchener 2004 46/243 5/130 38.0 % 4.92 [ 2.01, 12.08 ]
TOMBOLA 2009 285/2223 151/2216 50.0 % 1.88 [ 1.56, 2.27 ]
Subtotal (95% CI) 2626 2491 100.0 % 3.85 [ 1.27, 11.63 ]
Total events: 350 (Surveillance), 156 (Immediate colposcopy)
Heterogeneity: Tau2 = 0.63; Chi2 = 8.31, df = 2 (P = 0.02); I2 =76%
Test for overall effect: Z = 2.39 (P = 0.017)
2 Default rates at 12 months
Flannelly 1994 23/158 0/145 17.4 % 43.16 [ 2.65, 704.13 ]
Kitchener 2004 95/243 5/130 38.5 % 10.16 [ 4.24, 24.35 ]
TOMBOLA 2009 327/2223 151/2216 44.1 % 2.16 [ 1.80, 2.59 ]
Subtotal (95% CI) 2624 2491 100.0 % 6.60 [ 1.49, 29.29 ]
Total events: 445 (Surveillance), 156 (Immediate colposcopy)
Heterogeneity: Tau2 = 1.30; Chi2 = 15.78, df = 2 (P = 0.00037); I2 =87%
Test for overall effect: Z = 2.48 (P = 0.013)
3 Default rates at 24 months
Flannelly 1994 38/158 0/145 6.6 % 70.70 [ 4.38, 1140.47 ]
Shafi 1997 36/171 1/182 11.9 % 38.32 [ 5.31, 276.40 ]
ALTS 2003 110/675 4/673 30.9 % 27.42 [ 10.17, 73.93 ]
ALTS 2003 165/1164 15/1163 50.7 % 10.99 [ 6.52, 18.53 ]
Subtotal (95% CI) 2168 2163 100.0 % 19.10 [ 9.02, 40.43 ]
Total events: 349 (Surveillance), 20 (Immediate colposcopy)
Heterogeneity: Tau2 = 0.22; Chi2 = 4.84, df = 3 (P = 0.18); I2 =38%
Test for overall effect: Z = 7.71 (P < 0.00001)
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Analysis 7.1. Comparison 7 Histology at 24 months: immediate colposcopy versus cytological surveillance,
LSIL/mild dyskaryosis only, Outcome 1 CIN incidence at 24 months, after LSIL/mild dyskaryosis at baseline.
Review: Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
Comparison: 7 Histology at 24 months: immediate colposcopy versus cytological surveillance, LSIL/mild dyskaryosis only
Outcome: 1 CIN incidence at 24 months, after LSIL/mild dyskaryosis at baseline
Study or subgroup
Immediate
col-
poscopy
Cytological
surveillance Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 CIN2 incidence at 24 months
Flannelly 1994 32/145 12/158 46.3 % 2.91 [ 1.56, 5.42 ]
ALTS 2003 63/673 58/675 53.7 % 1.09 [ 0.78, 1.53 ]
Subtotal (95% CI) 818 833 100.0 % 1.72 [ 0.66, 4.48 ]
Total events: 95 (Immediate colposcopy), 70 (Cytological surveillance)
Heterogeneity: Tau2 = 0.42; Chi2 = 7.32, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.10 (P = 0.27)
2 CIN2+ incidence at 24 months
Flannelly 1994 98/145 44/158 49.6 % 2.43 [ 1.84, 3.20 ]
ALTS 2003 127/673 151/675 50.4 % 0.84 [ 0.68, 1.04 ]
Subtotal (95% CI) 818 833 100.0 % 1.43 [ 0.51, 4.01 ]
Total events: 225 (Immediate colposcopy), 195 (Cytological surveillance)
Heterogeneity: Tau2 = 0.54; Chi2 = 35.75, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 0.67 (P = 0.50)
3 CIN3+ incidence at 24 months
Flannelly 1994 66/145 32/158 49.6 % 2.25 [ 1.57, 3.21 ]
ALTS 2003 64/673 93/675 50.4 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 818 833 100.0 % 1.24 [ 0.39, 3.94 ]
Total events: 130 (Immediate colposcopy), 125 (Cytological surveillance)
Heterogeneity: Tau2 = 0.67; Chi2 = 24.63, df = 1 (P<0.00001); I2 =96%
Test for overall effect: Z = 0.36 (P = 0.72)
0.01 0.1 1 10 100
Cytological surveillance Immediate colposcopy
49Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
(Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.1. Comparison 8 Histology at 24 months: immediate colposcopy versus cytological surveillance,
excluding 1 trial, Outcome 1 Presence of CIN2 in histology at 24 months.
Review: Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
Comparison: 8 Histology at 24 months: immediate colposcopy versus cytological surveillance, excluding 1 trial
Outcome: 1 Presence of CIN2 in histology at 24 months
Study or subgroup
Immediate
col-
poscopy Surveillance Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Flannelly 1994 32/145 12/158 53.1 % 2.91 [ 1.56, 5.42 ]
Shafi 1997 8/182 10/171 46.9 % 0.75 [ 0.30, 1.86 ]
Total (95% CI) 327 329 100.0 % 1.54 [ 0.41, 5.78 ]
Total events: 40 (Immediate colposcopy), 22 (Surveillance)
Heterogeneity: Tau2 = 0.76; Chi2 = 5.80, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Surveillance Immediate colposcopy
50Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
(Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.2. Comparison 8 Histology at 24 months: immediate colposcopy versus cytological surveillance,
excluding 1 trial, Outcome 2 Presence of CIN2+ in histology at 24 months.
Review: Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
Comparison: 8 Histology at 24 months: immediate colposcopy versus cytological surveillance, excluding 1 trial
Outcome: 2 Presence of CIN2+ in histology at 24 months
Study or subgroup
Immediate
col-
poscopy Surveillance Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Flannelly 1994 98/145 44/158 52.1 % 2.43 [ 1.84, 3.20 ]
Shafi 1997 43/182 34/171 47.9 % 1.19 [ 0.80, 1.77 ]
Total (95% CI) 327 329 100.0 % 1.72 [ 0.86, 3.47 ]
Total events: 141 (Immediate colposcopy), 78 (Surveillance)
Heterogeneity: Tau2 = 0.22; Chi2 = 8.36, df = 1 (P = 0.004); I2 =88%
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Histology at 24 months: immediate colposcopy versus cytological surveillance,
excluding 1 trial, Outcome 3 Presence of CIN3+ in histology at 24 months.
Review: Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
Comparison: 8 Histology at 24 months: immediate colposcopy versus cytological surveillance, excluding 1 trial
Outcome: 3 Presence of CIN3+ in histology at 24 months
Study or subgroup
Immediate
col-
poscopy Surveillance Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Flannelly 1994 66/145 32/158 55.3 % 2.25 [ 1.57, 3.21 ]
Shafi 1997 35/182 24/171 44.7 % 1.37 [ 0.85, 2.20 ]
Total (95% CI) 327 329 100.0 % 1.80 [ 1.11, 2.92 ]
Total events: 101 (Immediate colposcopy), 56 (Surveillance)
Heterogeneity: Tau2 = 0.08; Chi2 = 2.66, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 2.39 (P = 0.017)
Test for subgroup differences: Not applicable
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Table 1. Reported individual outcomes in the included studies
Study Outcomes Immediate colposcopy
n/N (%)
Cytological surveillance
n/N (%)
RR + 95% CI
ALTS 2003(ASCUS) Histology at 18 months
a
CIN 2 61/1163 (5.2) 26/1164 (2.2) 2.35 [1.49, 3.69]
CIN 2+ 119/1163 (10.2) 92/1164 (7.9) 1.29 [1.00, 1.68]
CIN 3+ 58/1163 (5.0) 66/1164 (5.7) 0.88 [0.62, 1.24]
Histology at 24 months
CIN 2 61/1163 (5.2) 60/1164 (5.2) 1.02 [0.72,1.44]
CIN 2+ 119/1163 (10.2) 168/1164 (14.4) 0.71 [0.57, 0.88]
CIN 3+ 58/1163 (5.0) 108/1164 (9.3) 0.54 [0.39, 0.73]
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Table 1. Reported individual outcomes in the included studies (Continued)
Default rates:
Default rate at 24
months
15/1163 (1.3) 165/1164 (14.2) 10.99 [6.52, 18.53]
ALTS 2003(LSIL) Histology at 18 months
a
CIN 2 63/673 (9.4) 36/675 (5.3) 1.76 [1.18, 2.61]
CIN 2+ 127/673 (18.9) 95/675 (14.1) 1.34 [1.05, 1.71]
CIN 3+ 64/673 (9.5) 59/675 (8.7) 1.09 [0.78, 1.52]
Histology at 24 months
CIN 2 63/673 (9.4) 58/675 (8.6) 1.09 [0.78,1.53]
CIN 2+ 127/673 (18.9) 151/675 (22.4) 0.84 [0.68, 1.04]
CIN 3+ 64/673 (9.5) 93/675 (13.8) 0.69 [0.51, 0.93]
Default rates:
Default rate at 24
months
4/673 (0.6) 110/675 (16.3) 27.42 [10.17, 73.93]
Flannelly 1994 Histology at 6 months
HPV / Koilocytic atypia 13/145 (9.0) 28/160 (17.5) 0.52 [0.28, 0.95]
Any CIN 121/145 (83.4) 86/160 (53.8) 1.55 [1.32, 1.82]
CIN 1 23/145 (15.9) 27/160 (16.9) 0.94 [0.57, 1.56]
CIN 2 32/145 (22.1) 26/160 (16.3) 1.36 [0.85, 2.16]
CIN 2+ 98/145 (67.6) 59/160 (36.9) 1.83 [1.45, 2.31]
CIN 3+ 66/145 (45.5) 33/160 (20.6) 2.21 [1.55, 3.14]
Histology at 12 months
HPV / Koilocytic atypia 13/145 (9.0) 18/158 (11.4) 0.79 [0.40, 1.55]
Any CIN 121/145 (83.4) 96/158 (60.8) 1.37 [1.19, 1.59]
CIN 1 23/145 (15.9) 25/158 (15.8) 1.00 [0.60, 1.69]
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Table 1. Reported individual outcomes in the included studies (Continued)
CIN 2 32/145 (22.1) 26/158 (16.5) 1.34 [0.84, 2.14]
CIN 1 / 2 55/145 (37.9) 51/158 (32.3) 1.18 [0.86, 1.60]
CIN 2+ 98/145 (67.6) 71/158 (44.9) 1.50 [1.22, 1.85]
CIN 3+ 66/145 (45.5) 45/158 (28.5) 1.60 [1.18, 2.17]
Histology at 24 months
HPV / Koilocytic atypia 13/145 (9.0) 11/158 (7.0) 1.29 [0.60, 2.78]
Any CIN 121/145 (83.4) 53/158 (33.5) 2.49 [1.97, 3.13]
CIN 1 23/145 (15.9) 9/158 (5.7) 2.78 [1.33, 5.82]
CIN 2 32/145 (22.1) 12/158 (7.6) 2.91 [1.56, 5.42]
CIN 2+ 98/145 (67.6) 44/158 (27.8) 2.43 [1.84, 3.20]
CIN 3+ 66/145 (45.5) 32/158 (20.3) 2.25 [1.57, 3.21]
Default rates:
Default rate at 6months 0/145 (0) 19/160 (11.9) 35.37 [2.15, 580.52]
Default rate at 12
months
0/145 (0) 23/158 (14.6) 43.16 [2.65, 704.13]
Default rate at 24
months
0/145 (0) 38/158 (24.1) 70.70 [4.38, 1140.47]
Kitchener 2004 Histology at 12 months
Any CIN 83/130 (63.8) 71/243 (29.2) 2.19 [1.73, 2.76]
CIN 1 / 2 61/130 (46.9) 47/243 (19.3) 2.43 [1.77, 3.32]
CIN 3+ 22/130 (16.9) 24/243 (9.9) 1.71 [1.00, 2.93]
Default rates:
Default rate at 6months 5/130 (3.8) 46/243 (18.9) 4.92 [2.01, 12.08]
Default rate at 12
months
5/130 (3.8) 95/243 (39.1) 10.16 [4.24, 24.35]
GHQ caseness b Choice c No choice c
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Table 1. Reported individual outcomes in the included studies (Continued)
Baseline 134/233 (58) 119/241 (49) 1.16 [0.98, 1.38]
6 months (pre visit) 71/183 (39) 77/190 (41) 0.96 [0.75, 1.23]
6 months (post visit) 59/175 (34) 66/177 (37) 0.90 [0.68, 1.20]
12 months 40/135 (29) 35/127 (28) 1.08 [0.73, 1.58]
Shafi 1997 Histology at 18 months
a
CIN 2 8/182(4.4) 2/171 (1.1) 3.76 [0.81, 17.45]
CIN 2+ 43/182 (23.6) 16/171 (9.4) 2.53 [1.48, 4.31]
CIN 3+ 35/182 (19.2) 14/171(8.2) 2.35 [1.31, 2.45]
Histology at 24 months
HPV / Koilocytic atypia 92/182 (50.5) 57/171 (33.3) 1.52 [1.17, 1.96]
Any CIN 88/182 (48.4) 51/171 (29.8) 1.62 [1.23, 2.13]
CIN 1 45/182 (24.7) 17/171 (9.9) 2.49 [1.48, 4.17]
CIN 2 8/182 (4.4) 10/171 (5.8) 0.75 [0.30, 1.86]
CIN 2+ 43/182 (23.6) 34/171 (19.9) 1.19 [0.80, 1.77]
CIN 3+ 35/182 (19.2) 24/171 (14.0) 1.37 [0.85, 2.20]
Default rates:
Default rate at 24
months
1/182 (0.5) 36/171 (21.1) 38.32 [5.31, 276.40]
Tombola 2009 Histology at 30 months
a
CIN 2 181/2216 (8.2) 101/2223 (4.5) 1.80 [1.42, 2.28]
CIN 2+ 369/2216 (16.7) 269/2223 (12.1) 1.38 [1.19, 1.59]
CIN 3+ 188/2216 (8.5) 168/2223 (7.6) 1.12 [0.92, 1.37]
Histology at 36 months
CIN 2 181/2216 (8.2) 157/2223 (7.1) 1.16 [0.94, 1.42]
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Table 1. Reported individual outcomes in the included studies (Continued)
CIN 2+ 369/2216 (16.7) 350/2223 (15.7) 1.06 [0.93, 1.21]
CIN 3+ 188/2216 (8.5) 193/2223 (8.7) 0.98 [0.81, 1.18]
Default rates:
Default rate at 6months 151/2216 (6.8) 285/2223 (12.8) 1.88 [1.56, 2.27]
Default rate at 12
months
151/2216 (6.8) 327/2223 (14.7) 2.16 [1.80, 2.59]
Pain d
Any pain 304/782 (38.9) 145/968 (15.0) 2.60 [2.18, 3.09]
Moderate or more se-
vere
144/774 (18.6) 56/965 (5.8) 3.21 [2.39, 4.30]
Bleeding d
Any bleeding 366/781 (46.9) 166/967 (17.2) 2.73 [2.33, 3.19]
Moderate or more se-
vere
144/772 (18.6) 16/961 (1.7) 11.20 [6.74, 18.61]
Discharge d
Any discharge 267/780 (34.2) 83/964 (8.6) 3.98 [3.17, 4.99]
Moderate or more se-
vere
133/777 (17.1) 36/962 (3.7) 4.57 [3.20, 6.53]
Anxiety e
6 weeks 59/751 (7.9) 121/900 (13.4) 0.58 [0.43, 0.79]
12 months 190/1161 (16.4) 218/1130 (19.3) 0.85 [0.71, 1.01]
18 months 162/1050 (15.4) 177/1008 (17.6) 0.88 [0.72, 1.07]
24 months 179/1001 (17.9) 177/962 (18.4) 0.97 [0.81, 1.17]
30 months 146/949 (15.4) 143/887 (16.1) 0.95 [0.77, 1.18]
Depression f
6 weeks 50/757 (6.6) 68/902 (7.5) 0.88 [0.62, 1.25]
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Table 1. Reported individual outcomes in the included studies (Continued)
12 months 110/1162 (9.5) 132/1136 (11.6) 0.81 [0.64, 1.04]
18 months 106/1052 (10.1) 114/1016 (11.2) 0.90 [0.70, 1.15]
24 months 111/1001 (11.1) 104/964 (10.8) 1.03 [0.80, 1.32]
30 months 101/948 (10.7) 108/887 (12.2) 0.88 [0.68, 1.13]
For Immediate colposcopy, n = n at immediate colposcopy visit, possible follow-up excluded.
a Cumulative incidence during follow-up, excluding the exit examination or deferred treatment.
b GHQ caseness = GHQ (General Health Questionnaire) score ≥ 4.
c Analysis for this outcome between the original randomization groups.
d Based on Questionnaire 6 weeks after immediate colposcopy or first cytological surveillance visit.
e ≥ 11 on hospital anxiety and depression anxiety subscale
f ≥ 8 on hospital anxiety and depression subscale
A P P E N D I C E S
Appendix 1. Abbreviations
ASCUS: atypical squamous cells of undetermined significance
CI: confidence Interval
CIN: cervical intra-epithelial lesion
CKC: cold knife conization
HSIL: high-grade squamous intra-epithelial lesion
LC: laser conization
LEEP: loop electrosurgical excisional procedure
LLETZ: large loop excision of the transformation zone
LSIL: low-grade squamous intra-epithelial lesion
NETZ: needle excision of the transformation zone
RCT: randomised controlled trial
RR: risk ratio
SWETZ: straight wire excision of the transformation zone
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Appendix 2. CENTRAL search strategy
#1 MeSH descriptor Uterine Cervical Dysplasia, this term only
#2 MeSH descriptor Cervical Intraepithelial Neoplasiaexplode all trees
#3 cervi* near/5 (dysplasia or neoplasia)
#4 CIN*
#5 dyskaryosis or dyskaryosis
#6 LGSIL or LSIL or ASCUS
#7 (#1 OR #2 OR #3 OR #4 OR #5)
#8 MeSH descriptor Precancerous Conditions, this term only
#9 MeSH descriptor Early Detection of Cancer, this term only
#10 MeSH descriptor Carcinoma, Squamous Cell, this term only
#11 MeSH descriptor Neoplasms, Squamous Cell, this term only
#12 squamous near/5 lesion*
#13 precancer* or pre-cancer* or premalignan* or pre-malignan* or preneoplas* or pre-neoplas*
#14 (#8 OR #9 OR #10 OR #11 OR ( #12 AND #13 ))
#15 MeSH descriptor Cervix Uteri, this term only
#16 cervi*
#17 (#15 OR #16)
#18 (#14 AND #17)
#19 MeSH descriptor Vaginal Smears, this term only
#20 (cervi* or vagina*) and (smear* or screen* or test*)
#21 (#19 OR #20)
#22 (#7 OR #18 OR #21)
#23 MeSH descriptor Colposcopy, this term only
#24 colposcop*
#25 LLETZ or LEEP or NETZ or SWETZ or LC or CKC
#26 MeSH descriptor Biopsy explode all trees
#27 biops*
#28 transformation zone
#29 MeSH descriptor Conization explode all trees
#30 conization or conization
#31 excis*
#32 (#23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31)
#33 (#22 AND #32)
Appendix 3. MEDLINE search strategy
MEDLINE Ovid
1 Uterine Cervical Dysplasia/
2 Cervical Intraepithelial Neoplasia/
3 (cervi* adj5 (dysplasia or neoplasia)).mp.
4 CIN*.mp.
5 (dyskaryosis or dyskariosis).mp.
6 (LGSIL or LSIL or ASCUS).mp.
7 1 or 2 or 3 or 4 or 5 or 6
8 Precancerous Conditions/
9 Early Detection of Cancer/
10 Carcinoma, Squamous Cell/
11 Neoplasms, Squamous Cell/
12 (squamous adj5 lesion*).mp.
13 (precancer* or pre-cancer* or premalignan* or pre-malignan* or preneoplas* or pre-neoplas*).mp.
14 8 or 9 or 10 or 11 or 12 or 13
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15 Cervix Uteri/ or cervi*.mp.
16 14 and 15
17 Vaginal Smear/ or ((cervi* or vagina*) and (smear* or screen* or test*)).mp.
18 7 or 16 or 17
19 Colposcopy/
20 colposcop*.mp.
21 (LLETZ or LEEP or NETZ or SWETZ or LC or CKC).mp.
22 exp Biopsy/
23 biops*.mp.
24 transformation zone.mp.
25 Conization/
26 (conization or conization).mp.
27 excis*.mp.
28 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27
29 18 and 28
30 randomized controlled trial.pt.
31 controlled clinical trial.pt.
32 randomized.ab.
33 placebo.ab.
34 clinical trials as topic.sh.
35 randomly.ab.
36 trial.ti.
37 30 or 31 or 32 or 33 or 34 or 35 or 36
38 29 and 37
39 exp animals/ not humans.sh.
40 38 not 39
key:
mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject
heading word, unique identifier
pt=publication type
ab=abstract
ti=title
sh=subject heading
Appendix 4. Embase search strategy
1 uterine cervix dysplasia/
2 uterine cervix carcinoma in situ/
3 (cervi* adj5 (dysplasia or neoplasia)).mp.
4 CIN*.mp.
5 (dyskaryosis or dyskariosis).mp.
6 (LGSIL or LSIL or ASCUS).mp.
7 1 or 2 or 3 or 4 or 5 or 6
8 precancer/
9 early diagnosis/
10 squamous cell carcinoma/
11 (squamous adj5 lesion*).mp.
12 (precancer* or pre-cancer* or premalignan* or pre-malignan* or preneoplas* or pre-neoplas*).mp.
13 8 or 9 or 10 or 11 or 12
14 exp uterine cervix/ or cervi*.mp.
15 13 and 14
16 vagina smear/ or ((cervi* or vagina*) and (smear* or screen* or test*)).mp.
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17 7 or 15 or 16
18 colposcopy/
19 colposcop*.mp.
20 (LLETZ or LEEP or NETZ or SWETZ or LC or CKC).mp.
21 exp biopsy/
22 biops*.mp.
23 transformation zone.mp.
24 uterine cervix conization/
25 (conization or conization).mp.
26 excis*.mp.
27 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
28 17 and 27
29 crossover procedure/
30 double-blind procedure/
31 randomized controlled trial/
32 single-blind procedure/
33 random*.mp.
34 factorial*.mp.
35 (crossover* or cross over* or cross-over*).mp.
36 placebo*.mp.
37 (double* adj blind*).mp.
38 (singl* adj blind*).mp.
39 assign*.mp.
40 allocat*.mp.
41 volunteer*.mp.
42 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41
43 28 and 42
44 (exp Animal/ or Nonhuman/ or exp Animal Experiment/) not Human/
45 43 not 44
key:
mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device
trade name, keyword
WH A T ’ S N E W
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H I S T O R Y
Protocol first published: Issue 5, 2012
Review first published: Issue 1, 2017
Date Event Description
30 January 2017 Amended Minor corrections made to the summary of findings table.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The title has changed from ’Management of low-grade squamous intra-epithelial lesions of the uterine cervix repeat cytology versus
immediate referral to colposcopy’ to ’Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological
abnormalities in the absence of HPV test’ in order to better describe the applicability of the evidence only in the absence of HPV test.
None of outcomes included used continuous outcome measures and the methods described in the protocol to be applied on continuous
outcomeswere not needed and included in the review. If in a future update continuous outcomes are identified the followingmethodology
will be used. For continuous outcomes (e.g. anxiety, depression scores), we will extract the final value and standard deviation (SD) of
the outcome of interest and the number of patients assessed at endpoint in each treatment arm at the end of follow-up, in order to
estimate the mean difference (MD) (if trials measured outcomes on the same scale) or standardised mean differences (SMDs) (if trials
measured outcomes on different scales) between treatment arms and its standard error (SE).
Surveillance or immediate colposcopy after ASCUS or borderline dyskaryosis was also included. These lesions,which constitute the
majority of women with low-grade smear, have hence been included in most trials and represent a major proportion of the women
upon whom these results are applicable.
We decided to accept cytological surveillance in any setting, not only in primary care as eligible. Most of the included studies used
other than primary care setting for follow-up and we considered it appropriate to include them.
Subgroup analyses were not performed based on continent, study type, study quality and inclusion and exclusion criteria. We were able
to include only a few studies in each meta-analysis and were hence not able to conduct all planned subgroup analyses.
We used GRADE to assess the quality of evidence instead of just removing unpublished and low-quality studies from sensitivity analyses
due to GRADE being introduced only after the publication of the protocol.
62Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
(Review)
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